<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74561</article-id><article-id pub-id-type="doi">10.7554/eLife.74561</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Hematopoietic stem and progenitor cells improve survival from sepsis by boosting immunomodulatory cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-257947"><name><surname>Morales-Mantilla</surname><given-names>Daniel E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3459-6231</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257949"><name><surname>Kain</surname><given-names>Bailee</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257948"><name><surname>Le</surname><given-names>Duy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-176136"><name><surname>Flores</surname><given-names>Anthony R</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-257946"><name><surname>Paust</surname><given-names>Silke</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-206329"><name><surname>King</surname><given-names>Katherine Y</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5093-6005</contrib-id><email>kyk@bcm.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Graduate Program in Immunology, Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Pediatrics, Division of Infectious Diseases, Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Division of Infectious Diseases, Department of Pediatrics, UTHSC/McGovern Medical School</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>The Scripps Research Institute, Department of Immunology and Microbiology</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name><role>Reviewing Editor</role><aff><institution>Radboudumc Center for Infectious Diseases</institution><country>Netherlands</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Van der Meer</surname><given-names>Jos W</given-names></name><role>Senior Editor</role><aff><institution>Radboud University Medical Centre</institution><country>Netherlands</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>02</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e74561</elocation-id><history><date date-type="received" iso-8601-date="2021-10-08"><day>08</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-31"><day>31</day><month>01</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-10-28"><day>28</day><month>10</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.10.26.465915"/></event></pub-history><permissions><copyright-statement>© 2022, Morales-Mantilla et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Morales-Mantilla et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74561-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74561-figures-v1.pdf"/><abstract><p>New therapeutic strategies to reduce sepsis-related mortality are urgently needed, as sepsis accounts for one in five deaths worldwide. Since hematopoietic stem and progenitor cells (HSPCs) are responsible for producing blood and immune cells, including in response to immunological stress, we explored their potential for treating sepsis. In a mouse model of Group A <italic>Streptococcus</italic> (GAS)-induced sepsis, severe immunological stress was associated with significant depletion of bone marrow HSPCs and mortality within approximately 5–7 days. We hypothesized that the inflammatory environment of GAS infection drives rapid HSPC differentiation and depletion that can be rescued by infusion of donor HSPCs. Indeed, infusion of 10,000 naïve HSPCs into GAS-infected mice resulted in rapid myelopoiesis and a 50–60% increase in overall survival. Surprisingly, mice receiving donor HSPCs displayed a similar pathogen load compared to untreated mice. Flow cytometric analysis revealed a significantly increased number of myeloid-derived suppressor cells in HSPC-infused mice, which correlated with reduced inflammatory cytokine levels and restored HSPC levels. These findings suggest that HSPCs play an essential immunomodulatory role that may translate into new therapeutic strategies for sepsis.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>hematopoietic stem cell</kwd><kwd>hematopoietic progenitor cell</kwd><kwd>sepsis</kwd><kwd><italic>Streptococcus pyogenes</italic></kwd><kwd>MDSC</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01HL136333</award-id><principal-award-recipient><name><surname>King</surname><given-names>Katherine Y</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01HL134880</award-id><principal-award-recipient><name><surname>King</surname><given-names>Katherine Y</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35HL155672</award-id><principal-award-recipient><name><surname>King</surname><given-names>Katherine Y</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Gilliam Fellowship</award-id><principal-award-recipient><name><surname>Morales-Mantilla</surname><given-names>Daniel E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004917</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>CPRIT-RP180672</award-id><principal-award-recipient><name><surname>King</surname><given-names>Katherine Y</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA125123</award-id><principal-award-recipient><name><surname>King</surname><given-names>Katherine Y</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>RR024574</award-id><principal-award-recipient><name><surname>King</surname><given-names>Katherine Y</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Infusion of hematopoietic stem and progenitor cells rescues mice from lethal Group A streptococcal sepsis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Sepsis accounts for one in five deaths worldwide and is a common final pathway for many disease processes such as cancer, diabetes, and cardiovascular disease (<xref ref-type="bibr" rid="bib45">Rhee et al., 2019</xref>). Sepsis is an inflammatory syndrome largely driven by the activation of immune cells by pathogen associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) (<xref ref-type="bibr" rid="bib62">van der Poll et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Deutschman and Tracey, 2014</xref>). After recognizing these molecules via pattern recognition receptors, immune cells become activated and produce proinflammatory cytokines, notably interleukins IL-1, IL-6, interferons (IFNs), and tumor necrosis factor (TNF) that contribute to fever, vasodilation, and multiorgan dysfunction (<xref ref-type="bibr" rid="bib14">Deutschman and Tracey, 2014</xref>; <xref ref-type="bibr" rid="bib66">Yu et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Huang et al., 2005</xref>; <xref ref-type="bibr" rid="bib64">Wang et al., 2008</xref>). For patients that progress to septic shock, mortality rates remain as high as 40% (<xref ref-type="bibr" rid="bib41">Napolitano, 2018</xref>).</p><p>Leukopenia is a feature of severe sepsis that arises from apoptosis of peripheral immune cells and is an independent risk factor for death. To counteract the adverse effects of leukopenia, investigators have used immunotherapies such as GM-CSF (<xref ref-type="bibr" rid="bib30">Krebs et al., 2019</xref>) or granulocyte infusions in an attempt to restore leukocyte numbers and improve survival. These strategies have produced mixed results (<xref ref-type="bibr" rid="bib18">Estcourt et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">Mathias et al., 2015</xref>). The benefits of granulocyte infusions in cancer patients with fever and neutropenia are limited by the difficulty of obtaining sufficient cells and the short-lived nature of those cells (<xref ref-type="bibr" rid="bib23">Hidalgo et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Robinson and Marks, 2004</xref>).</p><p>Recent work from our group and others indicates that hematopoietic stem and progenitor cells (HSPCs) express surface receptors for cytokines, chemokines, and PAMPs (<xref ref-type="bibr" rid="bib27">Karpova et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Burberry et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Nagai et al., 2006</xref>; <xref ref-type="bibr" rid="bib53">Schürch et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Matatall et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Baldridge et al., 2011</xref>; <xref ref-type="bibr" rid="bib43">Pietras et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Takizawa et al., 2017</xref>) and respond rapidly upon direct and indirect stimulation by these signals. HSPCs, the progenitors of all blood and immune cells, are comprised of five subgroups of hematopoietic cells: hematopoietic stem cells (HSCs), which have long-term self-renewal capacity, and four types of multipotent progenitors (MPPs 1–4), which are defined by lower self-renewal capacity and myeloid or lymphoid differentiation biases (<xref ref-type="bibr" rid="bib64">Wang et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Morales-Mantilla and King, 2018</xref>; <xref ref-type="bibr" rid="bib8">Chambers et al., 2007</xref>; <xref ref-type="bibr" rid="bib56">Sun et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Rodriguez-Fraticelli et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Cabezas-Wallscheid et al., 2014</xref>). Immune responses induce HSPCs in the bone marrow (BM) to produce effector immune cells via a process called emergency hematopoiesis (<xref ref-type="bibr" rid="bib35">Matatall et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Pietras et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Takizawa et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Morales-Mantilla and King, 2018</xref>; <xref ref-type="bibr" rid="bib33">MacNamara et al., 2011</xref>; <xref ref-type="bibr" rid="bib36">Matatall et al., 2016</xref>). The capacity of HSPCs to directly detect pathogen-derived molecules, cytokines, and chemokines suggests that emergency granulopoiesis can be mobilized from even the most primitive hematopoietic progenitors and that HSPCs have an active role in fighting infections. However, the extent and mechanism by which HSPC responses contribute to immunity in the acute setting remain poorly defined.</p><p>We recently showed that chronic inflammatory stress impairs HSPC quiescence and self-renewal while promoting their activation and terminal differentiation (<xref ref-type="bibr" rid="bib36">Matatall et al., 2016</xref>). Upon direct sensing of inflammatory cytokines such as interferon-gamma (IFNγ), HSCs are dislodged from their normal position near quiescence-enforcing CXCL12-abundant reticular cells in the niche. Inflammatory signaling induces transcription factors such as Pu.1, CEBPb, and BATF2 (<xref ref-type="bibr" rid="bib35">Matatall et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Pietras et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Matatall et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Sato et al., 2020</xref>) to promote myeloid differentiation, leading to the expansion of granulocyte and monocyte populations. Disruption of the homeostatic balance of self-renewal and differentiation eventually leads to depletion of the progenitor compartment (<xref ref-type="bibr" rid="bib43">Pietras et al., 2016</xref>; <xref ref-type="bibr" rid="bib39">Morales-Mantilla and King, 2018</xref>; <xref ref-type="bibr" rid="bib36">Matatall et al., 2016</xref>). Collectively, these studies point toward a direct role for HSPCs in supplying the myeloid cells critical to the immune response against infection.</p><p>To test their contribution to immune responses during acute infection, we examined the role of HSPCs in a mouse model of <italic>Streptococcus pyogenes</italic> infection, also known as Group A <italic>Streptococcus</italic> (GAS). GAS is a common and clinically relevant pathogen that causes a plethora of diseases, from mild skin infections to life-threatening necrotizing fasciitis and sepsis (<xref ref-type="bibr" rid="bib64">Wang et al., 2008</xref>; <xref ref-type="bibr" rid="bib15">Efstratiou and Lamagni, 2016</xref>; <xref ref-type="bibr" rid="bib16">Emgård et al., 2019</xref>; <xref ref-type="bibr" rid="bib63">Walker et al., 2014</xref>). GAS infections can infiltrate the bloodstream and other organs, causing high systemic levels of inflammatory cytokines including IFNγ, TNF, IL-1, and IL-6. As HSPCs have been shown to activate and differentiate in response to these cytokines (<xref ref-type="bibr" rid="bib6">Burberry et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Matatall et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Pietras et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Takizawa et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Morales-Mantilla and King, 2018</xref>; <xref ref-type="bibr" rid="bib22">Gong et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Esplin et al., 2011</xref>; <xref ref-type="bibr" rid="bib12">Chou et al., 2012</xref>), in this study we sought to determine the role of HSPCs in immune responses against infections.</p><p>Here, we found that GAS infection significantly depletes HSPCs in the bone marrow (BM). We tested the idea of infusing HSPCs to restore the hematopoietic progenitor pool. Mice treated with HSPCs showed restored HSPC numbers in the BM, increased myeloid cell production, and significantly improved overall survival. Surprisingly, HSPC infusion did not reduce pathogen burden. Instead, HSPC infusion correlated with a significant increase in the abundance of myeloid-derived suppressor cells (MDSCs) and a dampening of overall systemic inflammation. In summary, our studies indicate that HSPCs contribute to survival from sepsis by supporting the production of immunosuppressive MDSCs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>GAS infection induces trafficking of myeloid cells from the BM into circulation</title><p>To characterize the impact of acute infections on the hematopoietic system, we inoculated mice by intramuscular injection of the hind leg with 2 × 10<sup>6</sup> colony forming units (CFU) of the model pathogen <italic>S. pyogenes</italic> strain MGAS315. To characterize differentiated hematopoietic populations during infection, we performed flow cytometric analysis of BM and peripheral blood (PB) lineage cells 24 hr after GAS infection (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and collected serum for cytokine analyses. BM characterization of lineage cells showed a significant decrease in BM monocytes (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) and granulocytes (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) with no change in BM B or T cells (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>). In contrast, PB lineage composition was significantly skewed toward myeloid cells with significantly higher circulating monocytes and granulocytes (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>) and lower lymphoid cells (<xref ref-type="fig" rid="fig1">Figure 1I and J</xref>). Serum cytokine characterization showed a significant increase in monocyte chemoattractant protein-1 (MCP-1; also known as CCL2) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). These results suggest that myeloid cells exit the BM into circulation following an MCP-1 gradient, consistent with prior studies showing MCP-1-driven mobilization during inflammation (<xref ref-type="bibr" rid="bib60">Tsou et al., 2007</xref>; <xref ref-type="bibr" rid="bib52">Schultze et al., 2019</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Group A <italic>Streptococcus</italic> (GAS) infection promotes a rapid myeloid cell response.</title><p>(<bold>A</bold>) Experimental time frame of GAS infection and bone marrow (BM) analysis. (<bold>B</bold>) Serum levels of monocyte chemoattractant protein-1 (MCP-1) of naïve and GAS-infected mice. Absolute number of (<bold>C</bold>) monocytes, (<bold>D</bold>) granulocytes, (<bold>E</bold>) B cells, and (<bold>F</bold>) F cells in the BM of naïve and infected mice. Relative abundance of (<bold>G</bold>) monocytes, (<bold>H</bold>) granulocytes, (<bold>I</bold>) B cells, and (<bold>J</bold>) T cells in the blood. (<bold>B–J</bold>) Data is representative of three independent experiments; n = 3–5 mice/group; statistical comparison done using unpaired t-test; *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.0001. Outliers were identified using the ROUT method (Q = 5%).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>BM and PB populations of lineage cells and serum MCP-1 levels.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Group A <italic>Streptococcus</italic> (GAS) infection and superinfection promotes exit of myeloid cells from bone marrow (BM) into circulation.</title><p>(<bold>A</bold>) Experimental time frame of superinfection and BM analysis. (<bold>B</bold>) Serum levels of monocyte chemoattractant protein-1 (MCP-1) of naïve and mice infected with GAS, flu, or both pathogens. Absolute number of (<bold>C</bold>) monocytes, (<bold>E</bold>) B cells, (<bold>G</bold>) granulocytes, and (<bold>I</bold>) T cells in the BM of naïve and infected mice. Relative abundance of blood (<bold>D</bold>) monocytes, (<bold>F</bold>) B cells, (<bold>H</bold>) granulocytes, and (<bold>J</bold>) T cells. (<bold>B–J</bold>) Data is representative of three independent experiments; n = 3–5; statistical comparison done using unpaired t-test; *p &lt; 0.05, **p &lt; 0.01,***p &lt; 0.001, ****p &lt; 0.0001.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>BM counts of HSPC populations of naïve, infected, and superinfected mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>GAS infection depletes bone marrow HSPCs without evidence of extramedullary hematopoiesis</title><p>After 24 hr of infection, the state of HSPCs in the infected mice were analyzed by flow cytometry of BM and spleen (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) (see <xref ref-type="table" rid="table1">Table 1</xref> for surface markers). BM cells were not gated for the common stem cell marker SCA1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), since it has been previously described to be non-specifically expressed during inflammatory stress (<xref ref-type="bibr" rid="bib3">Baldridge et al., 2011</xref>). The total number of HSPCs dropped significantly in just 24 hrs in GAS-infected mice (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). More specifically, HSPC subpopulations including HSCs, multipotent progenitor 3 (MPP3s), and MPP4s were significantly lower in GAS-infected mice (<xref ref-type="fig" rid="fig2">Figure 2D, E, and F</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Group A <italic>Streptococcus</italic> (GAS) infection depletes bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs) 24 hr post infection.</title><p>(<bold>A</bold>) Experimental time frame of GAS infection and BM analysis. (<bold>B</bold>) Flow plot of HSPC gating and representation of different surface expression of cKit and Sca-1 during infection. Plots are gated from lineage negative BM cells. (<bold>C–F</bold>) Absolute number of HSPCs, hematopoietic stem cells (HSCs), multipotent progenitors (MPP) 3, and MPP4 in the BM of naïve and GAS-infected mice. Spleen populations of (<bold>G</bold>) HSPCs, (<bold>H</bold>) HSC/MPP1, (<bold>I</bold>) MPP2, and (<bold>J</bold>) MMP3/4 identified by differential expression of CD150 and CD48. (<bold>C–J</bold>) Data is representative of three independent experiments; n = 4–5 mice/group; statistical comparison done using unpaired t-test; *p &lt; 0.05, **p &lt; 0.01. Outliers were identified using the ROUT method (Q = 5%).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>BM counts of HSPC populations of naïve and infected mice and spleen HSPC populations.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Superinfection further depletes hematopoietic stem and progenitor cells (HSPCs) and hematopoietic stem cells (HSCs) in the bone marrow (BM).</title><p>(<bold>A</bold>) Experimental design of superinfection. (<bold>B</bold>) Flow cytometry plots of HSPCs (LSK) and their phenotypic expression of surface c-Kit and Sca-1. (<bold>C–H</bold>) Absolute number of HSPC, HSCs, and multipotent progenitor (MPP) subpopulations in the BM of naïve, Group A <italic>Streptococcus</italic> (GAS)-infected, flu-infected, or superinfected mice. Data is representative of three independent experiments; n = 5 mice/group. Comparison was done using one-way ANOVA and Tukey’s correction for multiple comparisons; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>BM and PB levels of immune cells and MCP-1 during infection.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig2-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Surface markers for flow cytometry.</title><p>Hematopoietic cell populations identified by flow cytometry were characterized using the listed surface markers. Lineage (Lin) markers include Gr1, CD11b, B220, CD4, CD8, and Ter119.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Population</th><th align="left" valign="top">Markers</th></tr></thead><tbody><tr><td align="left" valign="top">HSC</td><td align="left" valign="top">Lin- ckit+ CD150+ CD48- CD34- Flk2-</td></tr><tr><td align="left" valign="top">CD41+ HSCs</td><td align="left" valign="top">Lin- ckit+ CD150+ CD48- CD34- Flk2- CD41+</td></tr><tr><td align="left" valign="top">Donor HSPCs</td><td align="left" valign="top">Lin- ckit+ Sca1+</td></tr><tr><td align="left" valign="top">HSPCs</td><td align="left" valign="top">Lin- ckit+</td></tr><tr><td align="left" valign="top">MPP1</td><td align="left" valign="top">Lin- ckit+ CD150+ CD48 CD34+ Flk2-</td></tr><tr><td align="left" valign="top">MPP2</td><td align="left" valign="top">Lin- ckit+ CD150+ CD48+ Flk2-</td></tr><tr><td align="left" valign="top">MPP3</td><td align="left" valign="top">Lin- ckit+ CD150 CD48+ CD34+ Flk2-</td></tr><tr><td align="left" valign="top">MPP4</td><td align="left" valign="top">Lin- ckit+ CD150 CD48+ CD34+ Flk2+</td></tr><tr><td align="left" valign="top">GMP</td><td align="left" valign="top">Lin- ckit+ CD41- CD150- CD16/32+</td></tr><tr><td align="left" valign="top">MkP</td><td align="left" valign="top">Lin- ckit+ CD150+ CD41+</td></tr><tr><td align="left" valign="top">Myeloid cells</td><td align="left" valign="top">Gr1+ Mac1+ B220- CD4- CD8-</td></tr><tr><td align="left" valign="top">B cells</td><td align="left" valign="top">Gr1- Mac1- B220+ CD4- CD8-</td></tr><tr><td align="left" valign="top">T cells</td><td align="left" valign="top">Gr1- Mac1- B220- CD4+ CD8 or Gr1- Mac1- B220- CD4- CD8+</td></tr><tr><td align="left" valign="top">Granulocytes</td><td align="left" valign="top">Gr1+ Mac1+ B220- CD4- CD8- SSC-mid F4/80-</td></tr><tr><td align="left" valign="top">Eosinophils</td><td align="left" valign="top">Gr1- Mac1+ B220- CD4- CD8- SSC<sup>Hi</sup></td></tr><tr><td align="left" valign="top">Macrophages</td><td align="left" valign="top">Gr1+ Mac1+ B220- CD4- CD8- SSC<sup>low</sup> F4/80+</td></tr><tr><td align="left" valign="top">Monocytes</td><td align="left" valign="top">Mac1+ B220- CD4- CD8- SSC<sup>low</sup></td></tr><tr><td align="left" valign="top">PMN-MDSC</td><td align="left" valign="top">CD11b + Ly6G + Ly6C<sup>low</sup>CD244+</td></tr><tr><td align="left" valign="top">M-MDSC</td><td align="left" valign="top">CD11b + Ly6G- Ly6C<sup>hi</sup></td></tr></tbody></table></table-wrap><p>Extramedullary hematopoiesis is the proliferation and differentiation of HSCs in tissues other than the BM, the canonical stem cell niche. The spleen is one of the most common sites of extramedullary hematopoiesis during infections (<xref ref-type="bibr" rid="bib65">Yang et al., 2020</xref>). To assess whether a reciprocal increase in extramedullary hematopoiesis accompanied the loss of HSPCs in the BM, we analyzed spleen tissue by flow cytometry. While there was a slight increase in total HSPCs in the spleen (<xref ref-type="fig" rid="fig2">Figure 2G</xref>), there was no significant change in spleen populations that include HSCs/MPP1, MPP2s, or MPP3/4 (<xref ref-type="fig" rid="fig2">Figure 2H-J</xref>). These findings suggest that the loss of BM HSPC populations is not principally a result of migration from the BM into the spleen, and other mechanisms such as terminal differentiation (<xref ref-type="bibr" rid="bib36">Matatall et al., 2016</xref>) also likely contribute to the noted HSPC depletion, as observed in other studies.</p></sec><sec id="s2-3"><title>GAS infection induces HSC myeloid differentiation</title><p>Activation of HSPCs by PAMPs or cytokines promotes their proliferation and differentiation (<xref ref-type="bibr" rid="bib40">Nagai et al., 2006</xref>; <xref ref-type="bibr" rid="bib35">Matatall et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Pietras et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Takizawa et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Morales-Mantilla and King, 2018</xref>; <xref ref-type="bibr" rid="bib2">Baldridge et al., 2010</xref>). To determine the lineage fate of endogenous HSPCs following GAS infection, we performed lineage tracing experiments using the tamoxifen-inducible KRT18-CreERT2: Rosa26-lox-STOP-lox-TdTomato mouse system (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Within the BM, <italic>Krt18</italic> is almost exclusively expressed in HSCs (<xref ref-type="bibr" rid="bib10">Chapple et al., 2018</xref>) and these mice do not have any immunological impairment that would change the severity of our infection model. Tamoxifen induction activates the CreERT2 protein in Krt18-expressing HSCs, resulting in irreversible TdTomato expression in HSCs and their newly formed progeny (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Krt18 lineage tracing of naïve and Group A <italic>Streptococcus</italic> (GAS)-infected hematopoietic stem cells (HSCs).</title><p>(<bold>A</bold>) Genetic model of KRT18-CreERT2:Rosa26-lox-STOP-lox-TdTomato mouse system. (<bold>B</bold>) Representative gating of TdTomato expression in negative control (left: Genotype: Krt18-CreERT2<sup>+</sup>) and tamoxifen-induced positive control (right: Genotype: KRT18-CreERT2<sup>+</sup>: Rosa26-lox-STOP-lox-TdTomato<sup>+/-</sup>). Percent of bone marrow (BM) (<bold>C</bold>) hematopoietic stem and progenitor cell (HSPC), (<bold>D</bold>) HSC, (<bold>E</bold>) CD41+ HSC, and (<bold>F</bold>) myeloid populations that are TdTomato+. Percent of BM (<bold>G</bold>) total monocytes, (<bold>H</bold>) granulocytes, (<bold>I</bold>) granulocyte/monocyte progenitor (GMP), (<bold>J</bold>) BM T cells, and (<bold>K</bold>) BM B cells that are TdTomato+. Percent of peripheral blood (PB) (<bold>L</bold>) total myeloid cells, (<bold>M</bold>) monocytes, (<bold>N</bold>) granulocytes, (<bold>O</bold>) T cells, and (<bold>P</bold>) B cells that are TdTomato+. Data representative of three independent experiments; (<bold>C–N</bold>) n = 5–7 mice/group. Statistical comparison done using unpaired t-tests; *p &lt; 0.05, **p &lt; 0.01.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Levels of newly generated cells in response to GAS infection.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig3-v1.tif"/></fig><p>After 5 days of intraperitoneal injections of tamoxifen, mice were inoculated with GAS or saline. Since the average mammalian cell cycle takes 24 hr, we decided to trace the lineage of hematopoiesis 72 hr post GAS infection. After these 72 hr, BM and PB was harvested for flow cytometric analysis. Analysis of the BM showed that GAS infection induced the production of new HSPCs, which includes short-term HSCs and MPPs (<xref ref-type="fig" rid="fig3">Figure 3C-D</xref>). In addition, there was significant labeling of CD41+ HSCs, a myeloid-biased and proinflammatory subset of HSCs (<xref ref-type="fig" rid="fig3">Figure 3E</xref>; <xref ref-type="bibr" rid="bib21">Gekas and Graf, 2013</xref>), and new cells of the myeloid lineage (<xref ref-type="fig" rid="fig3">Figure 3F-H</xref>). While we found a significant increase in new BM monocytes (<xref ref-type="fig" rid="fig3">Figure 3G</xref>), there was no significant change in the frequency of TdTomato-labeled granulocyte/monocyte progenitors (GMPs) (<xref ref-type="fig" rid="fig3">Figure 3I</xref>), which may simply reflect a rapid flow through this compartment to terminally differentiated populations. We also saw no statistically significant increase in BM granulocytes (<xref ref-type="fig" rid="fig3">Figure 3H</xref>); however, PB analysis showed a significant increase in new myeloid cells in both monocytic and granulocytic branches (<xref ref-type="fig" rid="fig3">Figure 3L-N</xref>). While there was a significant decrease in the production of new BM T cells (<xref ref-type="fig" rid="fig3">Figure 3J</xref>), there was no change in BM B cells (<xref ref-type="fig" rid="fig3">Figure 3K</xref>) nor PB T or B cells (<xref ref-type="fig" rid="fig3">Figure 3O–P</xref>). These data suggest that endogenous HSCs undergo rapid emergency myelopoiesis during GAS infection.</p></sec><sec id="s2-4"><title>HSPC infusion promotes survival in GAS-infected mice</title><p>Given that HSPCs are activated to divide and differentiate into immune effector cells upon inflammatory stimulation and we observed an acute loss of HSPCs in GAS-infected mice, we hypothesized that infusion of naïve HSPCs (Lin- Sca-1+ c-Kit+) into GAS-infected mice could improve pathogen clearance, reduce tissue damage, and prolong survival. To test this hypothesis, we infected mice with 2 × 10<sup>6</sup> CFU MGAS315 and then infused 10,000 FACS-purified HSPCs 24 hr later, when endogenous HSPCs are significantly decreased (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). This HSPC dose, equivalent to approximately 1.7 × 10<sup>7</sup> cells per m<sup>2</sup> body surface area, is significantly lower than the dose used for granulocyte infusions, typically between 10<sup>8</sup> and 10<sup>10</sup> cells per m<sup>2</sup> (<xref ref-type="bibr" rid="bib44">Price et al., 2015</xref>). On day 3 post infection, we harvested BM, limb tissue, and spleen to characterize BM populations and pathogen load (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Hematopoietic stem and progenitor cell (HSPC) infusion in Group A <italic>Streptococcus</italic> (GAS)-infected mice promotes survival and increases progenitor populations in the bone marrow (BM).</title><p>(<bold>A</bold>) Experimental design of BM analysis and colony forming unit (CFU) count after HSPC infusion. (<bold>B</bold>) Flow plot of HSPC gating and representation of different surface expression of cKit and Sca-1 during infection. Plots are gated from lineage negative BM cells. (<bold>C–H</bold>) Absolute numbers of HSPCs, hematopoietic stem cells (HSCs), and downstream progenitors in the BM of naïve, GAS-infected mice, and GAS-infected mice rescued with HSPCs. Quantified bacterial load in the (<bold>I</bold>) limb and (<bold>J</bold>) spleen of infected mice. (<bold>K</bold>) Experimental design of the survival study. (<bold>J</bold>) Survival curve of GAS-infected mice with or without HSPC infusion. Data representative of three independent experiments; (<bold>C–H</bold>) n = 5–7 mice/group, (I and J) n = 8–10 mice/group, (<bold>L</bold>) n = 9–10 mice/group. Statistical comparison done using (<bold>C–H</bold>) one-way ANOVA with Tukey’s correction for multiple comparisons or (I and J) unpaired t-tests. ns = not significant, *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, *****p &lt; 0.0001. Comparison of (<bold>L</bold>) survival was done using Log-rank (Mantel-Cox) test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>HSPC levels after infusion and survival data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig4-v1.tif"/></fig><p>BM characterization showed that HSPC infusion restored the relative abundance of HSPCs, HSCs, and myeloid-biased progenitors, such as MPP3s and GMPs, in the BM (<xref ref-type="fig" rid="fig4">Figure 4C-H</xref>). We observed that GAS-infected mice that received HSPCs showed lower morbidity than non-rescued mice, with improved overall body score and activity level. To assess survival, we performed Kaplan-Meier survival studies of GAS-infected mice in the absence or presence of HSPC rescue (<xref ref-type="fig" rid="fig4">Figure 4K</xref>). GAS-infected mice infused with HSPCs had significantly higher survival than non-rescued mice (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). However, to our surprise, HSPC infusion did not significantly affect the pathogen burden in the infected muscle (<xref ref-type="fig" rid="fig4">Figure 4I</xref>) or pathogen spread to other tissues (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). Overall, these findings suggest that HSPC infusion is beneficial during GAS infections and promotes survival by a mechanism other than pathogen clearance.</p></sec><sec id="s2-5"><title>Superinfection further depletes HSPCs in mice</title><p>To determine the extent of the protective potential of HSPC infusion during infections, we tested the efficacy of HSPC rescue in a mouse model of influenza and GAS superinfection. Here, we used a model of influenza and <italic>S. pyogenes</italic> (strain MGAS315) bacterial superinfection. Mice were infected with influenza (strain H1N1 PR8) by intranasal injection of 150 plaque-forming units (PFU). On day 3 post influenza virus infection, which represents peak viral replication for humans and mice (<xref ref-type="bibr" rid="bib1">Baccam et al., 2006</xref>; <xref ref-type="bibr" rid="bib55">Smith and Perelson, 2011</xref>), we injected mice with 2 × 10<sup>6</sup> CFU MGAS315 by IM inoculation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). On day 4 (24 hr post GAS infection), we analyzed BM and PB. Lin- cells in the BM showed phenotypical differences in surface expression of Sca-1 and c-Kit proteins depending on the pathogen combination (<xref ref-type="bibr" rid="bib3">Baldridge et al., 2011</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). In addition, superinfection caused a severe decrease in HSPCs and their subpopulations (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C–1H</xref>). Most notably, the absolute number of HSCs was reduced to 20–30% of a healthy mouse (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>).</p><p>We also analyzed BM and PB lineage populations of superinfected mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Similar to GAS-infected mice, superinfection led to an increase in serum levels of MCP-1 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>) that resulted in the exit of BM monocytes and BM granulocytes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C, G</xref>) into circulation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D, H</xref>). BM B cell and T cell numbers did not change (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E, I</xref>), while the abundance of circulating B and T cells was reduced in GAS-infected and superinfected mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F, J</xref>).</p></sec><sec id="s2-6"><title>HSPC infusion promotes survival in superinfected mice and increases levels of HSPCs and myeloid progenitors in the BM</title><p>The loss of HSPCs and HSCs was very prominent in superinfected mice, more so than in mice infected with GAS alone. Therefore, we hypothesized that an infusion of 10,000 HSPCs would also benefit mice in this model of superinfection (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). As expected, HSPC infusion significantly increased HSPCs and myeloid-biased progenitors in superinfected mice (<xref ref-type="fig" rid="fig5">Figure 5B-G</xref>). As seen in GAS-infected mice, HSPC infusion did not promote bacterial (<xref ref-type="fig" rid="fig5">Figure 5H</xref>) or viral (<xref ref-type="fig" rid="fig5">Figure 5I</xref>) clearance in superinfected mice. The spread of bacteria to the spleen was also unaffected by HSPC infusion (<xref ref-type="fig" rid="fig5">Figure 5J</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Hematopoietic stem and progenitor cell (HSPC) infusion in superinfected mice promotes survival without changing pathogen clearance.</title><p>(<bold>A</bold>) Experimental design of bone marrow (BM) analysis and colony forming unit (CFU) count post HSPC infusion in superinfected mice. (<bold>B–G</bold>) BM populations of HSPCs and downstream progenitors after HSPC infusion. Bacterial load in the (<bold>H</bold>) limb and (<bold>J</bold>) spleen of infected mice. (<bold>I</bold>) Viral load of mice with or without HSPC infusion. (<bold>K</bold>) Experimental design of the survival studies on superinfected mice. (<bold>L</bold>) Survival curve after HSPC infusion. Experiments are representative of three independent experiments. (<bold>B–J</bold>) Comparison done with unpaired t-test or Welch’s <italic>t</italic>-test. (<bold>B–G</bold>) n = 5, (<bold>H–J</bold>) n = 9–11, and (<bold>L</bold>) n = 9–10 mice per group. Comparison of (<bold>L</bold>) survival was done using Log-rank (Mantel-Cox) test. ns = not significant, *p &lt; 0.05.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>HSPC levels in superinfected mice after infusion and survival data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig5-v1.tif"/></fig><p>Despite the severity of the infection, superinfected mice that received an HSPC infusion (<xref ref-type="fig" rid="fig5">Figure 5K</xref>) had significantly improved survival compared to non-rescued mice (<xref ref-type="fig" rid="fig5">Figure 5L</xref>). This finding suggests that the protective properties of HSPC infusion are effective even in this very severe model of infection.</p></sec><sec id="s2-7"><title>HSPC infusion increases immunomodulatory MDSCs and prevents sepsis-induced cytokine exacerbation</title><p>Production of proinflammatory cues including IL1, IL6, IL8, TNF, and MIP1a is a key driver of morbidity during sepsis. Together, these cues contribute to systemic inflammatory response syndrome (SIRS), including fever, tachypnea, vasodilation, and circulatory collapse (<xref ref-type="bibr" rid="bib24">Huang et al., 2005</xref>; <xref ref-type="bibr" rid="bib25">Jaffer et al., 2010</xref>). These cytokines are independently associated with poor outcomes and death from sepsis in humans. Since we observed improved survival in mice receiving HSPC infusion without any changes in pathogen load, we hypothesized that HSPCs could impact immunomodulatory cell composition and the inflammatory response to severe infection. Upon analysis of PB and BM populations 3 days after infection and 2 days after HSPC infusion (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), there were no changes in BM or PB T lymphocytes that could indicate a Treg-related activity (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref> and 1B). However, we found that HSPC infusion significantly increased PB polymorphonuclear MDSCs (PMN-MDSCs) (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) and restored PB monocytic-MDSCs (M-MDSCs) levels (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) 3 days post infection and 2 days post HSPC infusion. Similarly, HSPC infusion restored BM PMN-MDSCs and M-MDSCs populations in GAS-infected mice (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>). These cells were functionally validated (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>) as immunosuppressive cells by their ability to reduce activated T cell proliferation in culture (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>). Strikingly, cytokine profiling 72 hr after GAS infection showed reduced overall levels of proinflammatory cytokines in GAS-infected mice that received HSPC infusion (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). These findings suggest that HSPC infusion supports the production of MDSC populations sufficient to dampen maladaptive proinflammatory cues during sepsis.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Hematopoietic stem and progenitor cell (HSPC) infusion increases and restores myeloid-derived suppressor cell (MDSC) populations and dampens inflammation after Group A <italic>Streptococcus</italic> (GAS).</title><p>(<bold>A</bold>) Representative gating of MDSCs by their surface expression of Ly6G and Ly6C at day 3 post infection. Gated on CD11b + cells. Peripheral blood (PB) populations of (<bold>B</bold>) polymorphonuclear MDSCs (PMN-MDSCs) and (<bold>C</bold>) monocytic-MDSCs (M-MDSCs) of naïve, GAS-infected, and GAS-infected mice infused with HSPCs. Bone marrow (BM) populations of (<bold>D</bold>) PMN-MDSCs and (<bold>E</bold>) M-MDSCs of naïve, GAS-infected, and GAS-infected mice infused with HSPCs. (<bold>F</bold>) Heatmap of serum cytokine levels using ClustVis web tool (<xref ref-type="bibr" rid="bib38">Metsalu and Vilo, 2015</xref>). Data representative of two (<bold>A–E</bold>) or four (<bold>F</bold>) independent experiments. (<bold>B–E</bold>) Statistical comparison done using one-way ANOVA with Tukey’s correction for multiple comparisons; n = 7 mice per group; *p &lt; 0.05, **p &lt; 0.01. Outliers were identified using the ROUT method (Q = 5%).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>BM and PB levels of MDSC populations and cytokine levels raw data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Myeloid-derived suppressor cells (MDSCs) reduce activated T cell proliferation.</title><p>The abundance of T cells in the (<bold>A</bold>) bone marrow (BM) and (<bold>B</bold>) peripheral blood (PB) of mice; n = 5–7 mice per group. (<bold>C</bold>) Experimental design of T cell suppression assay. Created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com">https://BioRender.com</ext-link>. (<bold>D</bold>) Flow cytometric measurement of T cell proliferation by dilution of CellTrace Violet dye. ‘M’ (monocytic) represents M-MDSCs and ‘PMN’ (polymorphonuclear) represents PMN-MDSCs. Data is representative of at least two experiments. Statistical comparison done using one-way ANOVA and Tukey’s correction for multiple comparisons; ***p &lt; 0.001, ****p &lt; 0.0001.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>T cell numbers after infusion and suppression assay data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-74561-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-8"><title>Infused HSPCs do not engraft but produce myeloid cells including MDSCs</title><p>In order to determine whether HSPCs infused in an infected mouse directly differentiate into MDSCs, we performed lineage tracing experiments using expression of the CD45.1 variant to distinguish infused HSPCs from endogenous CD45.2 cells. Mice were infected with GAS and then rescued with HSPCs 24 hr after GAS inoculation. Thirty days after infection, mice still showed signs of inflammation on the leg, indicating the inflammatory cues that drive HSPC activation and differentiation were still present. At 30 days after infection, the CD45.1+ cell compartment showed no HSCs but a low number of MPP1 and myeloid-biased MPP3s in the BM (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Lineage analysis in the BM showed that these cells gave rise to more myeloid cells compared to lymphoid. Furthermore, a fraction of the cells became new monocytic-MDSCs (M-MDSCs) and polymorphonuclear-MDSCs (PMN-MDSCs) (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Upon examination of the PB, circulating CD45.1 were primarily myeloid cells, with a small fraction identified as M-MDSCs and PMN-MDSCs (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Collectively, these data show that infused cells differentiate toward the myeloid lineage with no sign of stem cell engraftment. Whereas MDSCs did arise directly from infused cells, their numbers were not sufficient to account for the large increase in MDSCs observed in the HSPC-rescued mice. These data suggest that HSPC infusion contributes to MDSC expansion via both direct and indirect mechanisms.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Lineage fate of infused hematopoietic stem and progenitor cells (HSPCs) in Group A <italic>Streptococcus</italic> (GAS)-infected mice skews myeloid without signs of stem cell engraftment.</title><p>Gating representation of the lineage fate of (<bold>A</bold>) bone marrow (BM) HSPCs, (<bold>B</bold>) BM lineage cells, and (<bold>C</bold>) peripheral blood (PB) lineage cells 30 days after GAS infection. Data is representative of three independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we show HSPC infusion holds therapeutic potential for bacterial sepsis. Our studies demonstrate that GAS infection induces a robust myeloid response just 24 hr after infection and significantly depletes HSPC populations in the BM. After infection, endogenous HSPCs are driven to differentiate toward the myeloid lineage. However, this response is insufficient to prevent disease progression and pathogen dissemination, resulting in mortality in 5–7 days. While sepsis has been described to cause mobilization of HSPCs (<xref ref-type="bibr" rid="bib54">Skirecki et al., 2019</xref>), we did not find any evidence of HSC or MPP mobilization to the spleen. Strikingly, we found infusing just 10,000 HSPCs improved survival in GAS-infected mice and mice with GAS and influenza superinfection. This infusion was capable of increasing PB and BM hematopoietic populations of infected mice. Specifically, HSPC infusion restored BM HSPCs and both PB and BM MDSC populations. Importantly, HSPC infusion did not reduce pathogen burden, but contributed to survival via the generation of immunoregulatory cells that dampened maladaptive inflammatory signaling in infected mice.</p><p>The hematopoietic and immune systems are comprised of immune cells with antimicrobial killing capacity as well as various types of immunomodulatory cells such as MDSCs, regulatory B cells (Bregs), and regulatory T cells (Tregs) (<xref ref-type="bibr" rid="bib34">Maizels and Smith, 2011</xref>; <xref ref-type="bibr" rid="bib48">Rosser and Mauri, 2015</xref>; <xref ref-type="bibr" rid="bib51">Schrijver et al., 2019</xref>). In the short time frame of acute sepsis, myeloid cells such as neutrophils, monocytes, and macrophages are of critical importance in rapidly recognizing and killing invading bacteria. Our data demonstrate that these cells and even the progenitors that produce them in the BM can be rapidly depleted during a severe acute infection. Furthermore, lineage tracing experiments provide the first direct evidence that terminally differentiated myeloid cells are rapidly produced from the level of the HSC during an acute infection. Initially we hypothesized that replacement of HSPCs may improve outcomes from acute bacterial infection by boosting the availability of myeloid cells to kill bacteria. While myeloid cell populations were somewhat restored after HSPC infusion, this was insufficient to reduce pathogen burden.</p><p>Dysregulated inflammation is one of the main drivers of morbidity and mortality during infections (<xref ref-type="bibr" rid="bib24">Huang et al., 2005</xref>; <xref ref-type="bibr" rid="bib20">Frank and Paust, 2020</xref>; <xref ref-type="bibr" rid="bib26">Karki et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Fajgenbaum and June, 2020</xref>). For example, excessive inflammatory responses are a common result of seasonal influenza (<xref ref-type="bibr" rid="bib66">Yu et al., 2011</xref>; <xref ref-type="bibr" rid="bib20">Frank and Paust, 2020</xref>) and SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib26">Karki et al., 2021</xref>). Seasonal influenza increases the susceptibility of patients to secondary bacterial infections or superinfection (<xref ref-type="bibr" rid="bib49">Rynda-Apple et al., 2015</xref>). Superinfections exacerbate the proinflammatory environment of common viral infections and are associated with increased morbidity and mortality (<xref ref-type="bibr" rid="bib49">Rynda-Apple et al., 2015</xref>; <xref ref-type="bibr" rid="bib42">Paget and Trottein, 2019</xref>). To our surprise, HSPC infusion was protective in a model of influenza and GAS superinfection, suggesting that its protective effects are robust even in the setting of severe inflammation. In our mouse models, infection dramatically increased cytokine levels within just 3 days of infection. Interestingly, HSPC infusion was accompanied by an overall decrease in serum cytokine levels and a specific dampening of cytokines involved in ‘cytokine storm’ (<xref ref-type="bibr" rid="bib24">Huang et al., 2005</xref>; <xref ref-type="bibr" rid="bib26">Karki et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Fajgenbaum and June, 2020</xref>). HSPCs have been described to produce cytokines, indicating that they have the capacity to direct immune function (<xref ref-type="bibr" rid="bib11">Chen et al., 2016</xref>). However, whether the cytokines produced by HSPCs themselves contribute to the regulation of the immune response has heretofore been unknown. Our data point toward an immunomodulatory role of HSPC infusion that could prevent immune dysregulation during sepsis.</p><p>Immunoregulatory cells in the hematopoietic system include Tregs, Bregs, and MDSCs (<xref ref-type="bibr" rid="bib34">Maizels and Smith, 2011</xref>; <xref ref-type="bibr" rid="bib51">Schrijver et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Uhel et al., 2017</xref>). Perhaps the most recognized immunomodulatory cell known is the Treg. While Tregs have essential roles regulating immune responses to pathogens (<xref ref-type="bibr" rid="bib34">Maizels and Smith, 2011</xref>), we did not see differences in any lymphocyte population, including T cells, that would suggest a Treg-mediated anti-inflammatory mechanism after HSPC infusion. MDSCs are immature myeloid cells that have strong anti-inflammatory roles by suppressing the responses of T-helper cells that contribute to the development of sepsis (<xref ref-type="bibr" rid="bib51">Schrijver et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Köstlin et al., 2017</xref>; <xref ref-type="bibr" rid="bib13">Delano et al., 2007</xref>). PMN-MDSCs and M-MDSCs have strong anti-inflammatory functions that can be beneficial or detrimental depending on the setting. In fact, some studies have shown that MDSCs contribute to clinical worsening during sepsis (<xref ref-type="bibr" rid="bib51">Schrijver et al., 2019</xref>). For almost three decades, increased circulating immature myeloid cells have been a clinical marker of SIRS (<xref ref-type="bibr" rid="bib5">Bone et al., 1992</xref>). Interestingly, increased MDSCs during sepsis have also been associated with increased development of nosocomial infections (<xref ref-type="bibr" rid="bib61">Uhel et al., 2017</xref>). However, in our GAS model of accelerated infection, the increase in MDSC populations after HSPC infusion was accompanied by lower overall cytokine levels and increased survival, suggesting that the immunomodulatory functions of MDSCs are beneficial during the early stages of systemic inflammation and could prevent sepsis-related mortality (<xref ref-type="bibr" rid="bib9">Chang et al., 2018</xref>).</p><p>An important limitation of our study is that the lineage fate and the tissue or organ destination of the infused HSPCs at the early stages of infusion remain unknown. The small number of cells infused makes it challenging to identify them in the pool of endogenous cells of the recipient mice. While our data suggest that infused HSPCs directly and indirectly boost MDSC production by endogenous cells, further work will be required to determine the mechanisms by which HSPCs contribute to MDSC expansion. In addition, further analysis of HSPC subpopulations will be required to determine if long-term HSCs or short-lived MPPs confer the greatest therapeutic potential. Identifying a short-lived hematopoietic progenitor that can signal endogenous cells to restore MDSC populations could represent a promising alternative therapeutic avenue (<xref ref-type="bibr" rid="bib23">Hidalgo et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">Karpova et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Nagai et al., 2006</xref>) to treat sepsis while avoiding concern of possible graft versus host disease complications (<xref ref-type="bibr" rid="bib4">Batsali et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Tijaro-Ovalle et al., 2019</xref>).</p><p>Currently, G-CSF, GM-CSF, and granulocyte transfusion (<xref ref-type="bibr" rid="bib46">Robinson and Marks, 2004</xref>; <xref ref-type="bibr" rid="bib44">Price et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Klein and Castillo, 2017</xref>) are used to prevent or treat sepsis in oncology patients with chemotherapy-induced fever and neutropenia. However, the clinical efficacy of granulocyte transfusion is poor (<xref ref-type="bibr" rid="bib44">Price et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Klein and Castillo, 2017</xref>). Here, we have shown infusing HSPCs is a promising alternative to granulocyte transfusion. Current granulocyte doses in humans are around 1 × 10<sup>10</sup> cells per m<sup>2</sup> body surface area given daily or every other day (<xref ref-type="bibr" rid="bib44">Price et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Teofili et al., 2016</xref>). Our infusion model only uses a single dose of 1.7 × 10<sup>7</sup> cells per m<sup>2</sup> body surface area (or 10,000 HSPCs in a mouse). It is important to emphasize that 10,000 HSPCs is a relatively small number of cells to infuse into a mouse as it represents less than 0.01% of the nucleated BM cells in a mouse. Collectively, the single low HSPC dose compared to multiple larger granulocyte transfusions suggests that HSPCs are more effective than granulocytes, cell for cell, in the treatment of sepsis. While the path to a clinical application can be long, our findings could lead to the future development of a new therapeutic approach that could succeed where granulocyte infusions have fallen short.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">American Hamster monoclonal Anti-mouse CD3e</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Clone 145–2C11 (Cat. No. 100301)</td><td align="left" valign="bottom">(2 µg/mL) RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312666">AB_312666</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Syrian Hamster monoclonal anti-mouse CD28</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Clone 37.51 (Cat. No. 102101)</td><td align="left" valign="bottom">(2 µg/mL)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312866">AB_312866</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal anti-mouse Gr1-PECy5</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone RB6-8C5 (Cat. No. 15-5931-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_468813">AB_468813</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-Mouse CD11b PE-Cyanine5</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone M1/70 (Cat. No. 15-0112-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_468714">AB_468714</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat MonoclonalAnti-Human/Mouse CD45R (B220) PE-Cyanine5</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone RA3-6B2 (Cat. No. 15-0452-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_468755">AB_468755</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal ANTI-MOUSE CD4 PE-Cy5</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone GK1.5 (Cat. No. 15-0041-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_469532">AB_469532</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-Mouse CD8a PE-Cyanine5</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone 53–6.7 (Cat. No. 15-0081-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_468706">AB_468706</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-Mouse TER-119 PE-Cyanine5</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone TER119 (Cat. No. 15-5921-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_468810">AB_468810</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse Sca-1 Pacific Blue</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Clone D7 (Cat. No. 108120)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493273">AB_493273</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-mouse Ly-6G</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Clone 1A8 (Cat. No. 127605)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1236488">AB_1236488</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonalAnti-Mouse CD45.1 PE</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Clone A20 (Cat. No.110707)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313496">AB_313496</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal anti-mouse CD117 (c-Kit) APC-eFluor 780</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone 2B8 (CaT. No. 47-1171-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1272177">AB_1272177</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat MonoclonalAnti-Mouse CD150 PECy7</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Clone TC15-12F12.2 (Cat. No. 115914)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_439797">AB_439797</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">American Hamster Monoclonal Anti-mouse CD48 APC</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone HM48-1 (Cat. No. 17-0481-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_469408">AB_469408</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-Mouse CD34 FITC</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone RAM34 (11-0341-82)</td><td align="left" valign="bottom">(1:50)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_465021">AB_465021</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-Mouse CD135 DyLight680</td><td align="left" valign="bottom">Novus</td><td align="left" valign="bottom">Clone A2F10 (Cat. No. NBP1-43352FR)</td><td align="left" valign="bottom">(1:50)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2904163">AB_2904163</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-Mouse CD16/32 BV605</td><td align="left" valign="bottom">BD</td><td align="left" valign="bottom">Clone 2.4G2 (93) (Cat. No. 563006)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2737947">AB_2737947</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti Mouse CD41 BV480</td><td align="left" valign="bottom">BD</td><td align="left" valign="bottom">Clone MWReg30 (Cat. No. 746554)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2743844">AB_2743844</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-mouse Ly-6C APC</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Clone HK1.4 (Cat. No. 128016)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1732076">AB_1732076</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-mouse CD244 PECy7</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Clone eBio244F4 (Cat. No. 25-2441-82)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2573432">AB_2573432</ext-link></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Monoclonal Anti-Mouse F4/80 Pacific Blue</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Clone BM8 (Cat. No. MF48028)</td><td align="left" valign="bottom">(1:100)RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1500083">AB_1500083</ext-link></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin-Streptomycin</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">(Cat. No. 15140122)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hanks' Balanced Salt Solution</td><td align="left" valign="bottom">Gibco/Thermofisher</td><td align="left" valign="bottom">HBSS (Cat. No. 14170161)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES (1M)</td><td align="left" valign="bottom">Gibco/Thermofisher</td><td align="left" valign="bottom">Cat. No. 15630080</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">Sigma</td><td align="char" char="." valign="bottom">(Cat. No. 10540-29-1)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CD117 Microbeads</td><td align="left" valign="bottom">Miltenyi-Biotec</td><td align="char" char="." valign="bottom">(Cat. No. 130-091-224)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CD3e Microbead Kit, Mouse</td><td align="left" valign="bottom">Miltenyi-Biotec</td><td align="char" char="." valign="bottom">(Cat. No. 130-094-973)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Invitrogen SuperScript IV First-Strand Synthesis System</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">(Cat. No. 18091050)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">iTaq Universal SYBR Green Supermix; BioRad</td><td align="left" valign="bottom">Bio Rad</td><td align="char" char="." valign="bottom">(Cat. No. 172–5121)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant Mouse IL-2</td><td align="left" valign="bottom">Biolegend</td><td align="char" char="." valign="bottom">(Cat. No. 575404)</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Nucleoprotein (NP) Forward primer</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">NP F1</td><td align="left" valign="bottom">5'-GGGTGAGAATGGACGAAAAAC-3'</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Nucleoprotein (NP) Reverse primer</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">NP R1</td><td align="left" valign="bottom">5'-GATCCATCATTGCTTTTTGTGCA-3'</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ClustVis</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Metsalu and Vilo, 2015</xref></td><td align="left" valign="bottom">ClustVis</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_017133">SCR_017133</ext-link></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">KRT18-CreERT2: Rosa26-lox-STOP-lox-TdTomato</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Tamoxifen-inducible Cre system</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57Bl/6J</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #000664</td><td align="left" valign="bottom">Wildtype mouse line – CD45.2RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">B6.SJL-<italic>Ptprc<sup>a</sup> Pepc<sup>b</sup></italic>/BoyJ</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Strain #002014</td><td align="left" valign="bottom">C57Bl/6J congenic strain - CD45.1RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:002014">IMSR_JAX:002014</ext-link></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Streptococcus pyogenes</italic>)</td><td align="left" valign="bottom">Group A <italic>Streptococcus</italic></td><td align="left" valign="bottom">clinical isolate</td><td align="left" valign="bottom">MGAS315, <italic>emm3</italic> genotype, Serotype M3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Orthomyxoviridae, influenza virus A</italic>)</td><td align="left" valign="bottom">Influenza A virus</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">PR8 H1N1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CellTrace Violet Cell Proliferation Kit, for flow cytometry</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">(Cat. No. C34571)</td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>We used WT C57Bl/6 (CD45.2) (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link>) and C57Bl/6.SJL (CD45.1) (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:002014">IMSR_JAX:002014</ext-link>) mice 8–10 weeks of age. Lineage tracing using KRT18-CreERT2: Rosa26-lox-STOP-lox-TdTomato we made by crossing KRT18-CreERT2 mice obtained from Dr Daisuke Nakada (Baylor College of Medicine) and Rosa26-lox-STOP-lox-TdTomato mice (stock # 007914) obtained from Jackson Laboratories (Bar Harbor, ME, <ext-link ext-link-type="uri" xlink:href="https://www.jax.org">https://www.jax.org</ext-link>). All mice genotypes were confirmed by polymerase chain reaction (PCR) prior to the start of the experiments. Mice were assigned to each experimental group at random. Both male and female mice were used for all the experiments except for the superinfection survival studies as it has been shown that female mice have long-lasting hyperresponsiveness to respiratory infections (<xref ref-type="bibr" rid="bib31">Larcombe et al., 2011</xref>). Therefore, only male mice were used in the superinfection experiments. Individual mice were assigned to groups randomly and were age and sex-matched for each independent experiment.</p></sec><sec id="s4-2"><title>Pathogen inoculation and quantification</title><p>Mice were infected with <italic>S. pyogenes</italic> strain MGAS315 by intramuscular injection on the hind limb with 2 × 10<sup>6</sup> CFU. To determine the bacterial load, limb, spleen, and blood were collected from infected mice. Limb and spleen tissue were homogenized, serially diluted, and plated on blood agar plates (BAP) (BD, Franklyn Lake, NJ, <ext-link ext-link-type="uri" xlink:href="https://www.bd.com">https://www.bd.com</ext-link>). Blood was serially diluted and plated on BAP. Limb and spleen bacterial load was normalized to the grams of tissue that was homogenized.</p><p>Influenza A H1N1 PR8 strain infections were done by intranasal inoculation with 150 PFU. Viral load was quantified by collecting viral particles from lung lavage fluid using Amicon Ultra 0.5 mL (Millipore Sigma, Burlington, MA, <ext-link ext-link-type="uri" xlink:href="https://www.emdmillipore.com">https://www.emdmillipore.com</ext-link>), and RNA was purified using the TRIZOL method followed by the quantification of viral particles by real-time PCR of virus-specific nucleoprotein gene. The exact quantity was calculated using a standard curve of purified viral particles with known concentration and normalized by the amount of lung tissue collected.</p></sec><sec id="s4-3"><title>HSPC isolation and purification</title><p>Six bones were collected from naïve donor mice (two tibias, two femurs, and two hip bones). Bones were then carefully crushed in HBSS media with 1% penicillin/streptomycin and HEPES. Filtered BM was RBC lysed using 5 min RBC lysis buffer (Biolegend, San Diego, CA, <ext-link ext-link-type="uri" xlink:href="https://www.biolegend.com">https://www.biolegend.com</ext-link>). Lysis buffer was washed out and cells were stained with anti-CD117 magnetic beads (eBiosciences, San Diego, CA, <ext-link ext-link-type="uri" xlink:href="https://www.thermofischer.com">https://www.thermofischer.com</ext-link>) using the manufacturer’s protocol. CD117+ cells were positively selected using the AutoMACS instrument (Miltenyi). CD117+ cells were washed and stained for Lineage markers (<xref ref-type="table" rid="table1">Table 1</xref>) and Sca-1. After staining, HSPCs were purified by cell sorting.</p></sec><sec id="s4-4"><title>Flow cytometry and cell sorting</title><p>Flow cytometry analyses were done using LSR II and BD Fortessa instruments. Cells were identified by the differential expression of markers listed in <xref ref-type="table" rid="table1">Table 1</xref>. Our cocktail of Lineage (Lin) markers include Gr1, CD11b, B220, CD4, CD8, and Ter119.</p><p>Cell sorting of HSPCs and their subpopulations were done using the SONY SH800 sorter and the BD FACS Aria Fusion using the markers listed in <xref ref-type="table" rid="table1">Table 1</xref>. Post-sort purity test showed that sorted cells were 95–98% pure.</p></sec><sec id="s4-5"><title>Cre induction</title><p>Cre activation in KRT18-CreERT2: Rosa26-lox-STOP-lox-TdTomato was induced with tamoxifen. Each mouse was administered tamoxifen by intraperitoneal injection at a dose of 100 mg/kg body weight for 5 consecutive days prior to the start of the lineage tracing experiments.</p></sec><sec id="s4-6"><title>Cell infusion</title><p>All infusions were done intravenously by retroorbital injection. Rescued mice received cells resuspended in saline solution while the control mice were injected with saline solution alone.</p></sec><sec id="s4-7"><title>Cytokine profiling</title><p>Serum was collected using a BD Microtainer blood collection tube (San Jose, CA, <ext-link ext-link-type="uri" xlink:href="https://www.bdbiosciences.com">https://www.bdbiosciences.com</ext-link>). Serum levels of cytokines were analyzed through Eve Technologies company (Calgary, AB, Canada, <ext-link ext-link-type="uri" xlink:href="https://www.evetechnologies.com">https://www.evetechnologies.com</ext-link>).</p></sec><sec id="s4-8"><title>T cell suppression assay</title><p>T cells were isolated from the spleen using anti-CD3 magnetic beads from Miltenyi Biotec (Bergisch Gladbach, Germany, <ext-link ext-link-type="uri" xlink:href="https://www.miltenyibiotec.com">https://www.miltenyibiotec.com</ext-link>) and MDSCs were sorted using the SONY SH800 sorter and the BD FACS Aria Fusion as described above. T cell were activated with anti-CD3 and anti-CD28 coated plates and supplemented with IL-2 to support proliferation and then cultured alone of with M-MDSCs or PMN-MDSCs. T cells were stained with CellTrace Violet and proliferation was measured by dye dilution using flow cytometry.</p></sec><sec id="s4-9"><title>Statistical tests</title><p>Normality was assessed using the Shapiro-Wilk test and variances were compared using F-tests. Comparisons between two groups were made done using unpaired <italic>t</italic>-test for parametric data, Welch’s <italic>t</italic>-test for parametric data without equal variances, and Mann-Whitney test for non-parametric data. Tests involving three or more comparisons were done using one-way ANOVA with Tukey’s correction for multiple comparisons or Kruskal-Wallis test with Dunn’s correction for multiple comparisons. Comparisons of survival curves were done using Mantel-Cox tests. Outliers were identified using the ROUT method (Q = 5%). Graphs are shown as mean ± SEM. Sample size of each experiment was calculated based on pilot experiments and using an alpha = 0.05 and power = 0.80. Each specific statistical test used as well as group size and independent experiments are described on each figure legend.</p></sec><sec id="s4-10"><title>Study approval</title><p>Mice are housed in AAALAC-accredited, specific-pathogen-free animal facilities at Baylor College of Medicine and Texas Children’s Hospital. All experiments are approved and follow the guidelines stated in our protocol approved by the Institutional Animal Care and Use Committee (IACUC) and by the Baylor College of Medicine institutional review board.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Funding acquisition, Project administration, Supervision, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocol (#4802) of Baylor College of Medicine.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-74561-transrepform1-v1.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors would like to thank Catherine Gillespie, Maksim Mamonkin, Meghan Kisiel, Olumide Ayeni, and members of the King lab for their input into the study. DEMM and KYK were supported by the NIH grants R01HL136333, R01HL134880, and R35HL155672 (KYK). DEMM was also supported by the Howard Hughes Medical Institute (HHMI) Gilliam Fellowship for Advanced Study. This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the CPRIT Core Facility Support Award (CPRIT-RP180672), the NIH (CA125123 and RR024574), and the assistance of Joel M Sederstrom. This project was also assisted by the Dan L Duncan Cancer Center and the William T Shearer Center for Human Immunobiology.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baccam</surname><given-names>P</given-names></name><name><surname>Beauchemin</surname><given-names>C</given-names></name><name><surname>Macken</surname><given-names>CA</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Kinetics of influenza A virus infection in humans</article-title><source>Journal of Virology</source><volume>80</volume><fpage>7590</fpage><lpage>7599</lpage><pub-id pub-id-type="doi">10.1128/JVI.01623-05</pub-id><pub-id pub-id-type="pmid">16840338</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldridge</surname><given-names>MT</given-names></name><name><surname>King</surname><given-names>KY</given-names></name><name><surname>Boles</surname><given-names>NC</given-names></name><name><surname>Weksberg</surname><given-names>DC</given-names></name><name><surname>Goodell</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection</article-title><source>Nature</source><volume>465</volume><fpage>793</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/nature09135</pub-id><pub-id pub-id-type="pmid">20535209</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldridge</surname><given-names>MT</given-names></name><name><surname>King</surname><given-names>KY</given-names></name><name><surname>Goodell</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Inflammatory signals regulate hematopoietic stem cells</article-title><source>Trends in Immunology</source><volume>32</volume><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.it.2010.12.003</pub-id><pub-id pub-id-type="pmid">21233016</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batsali</surname><given-names>AK</given-names></name><name><surname>Georgopoulou</surname><given-names>A</given-names></name><name><surname>Mavroudi</surname><given-names>I</given-names></name><name><surname>Matheakakis</surname><given-names>A</given-names></name><name><surname>Pontikoglou</surname><given-names>CG</given-names></name><name><surname>Papadaki</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The Role of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles (MSC-EVs)</article-title><source>In Normal and Abnormal Hematopoiesis and Their Therapeutic Potential. Journal of Clinical Medicine</source><volume>9</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3390/jcm9030856</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>RC</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Cerra</surname><given-names>FB</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Fein</surname><given-names>AM</given-names></name><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Schein</surname><given-names>RMH</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis</article-title><source>Chest</source><volume>101</volume><fpage>1644</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1378/chest.101.6.1644</pub-id><pub-id pub-id-type="pmid">1303622</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burberry</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>MY</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Wicks</surname><given-names>I</given-names></name><name><surname>Inohara</surname><given-names>N</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name><name><surname>Núñez</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Infection mobilizes hematopoietic stem cells through cooperative NOD-like receptor and Toll-like receptor signaling</article-title><source>Cell Host &amp; Microbe</source><volume>15</volume><fpage>779</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2014.05.004</pub-id><pub-id pub-id-type="pmid">24882704</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabezas-Wallscheid</surname><given-names>N</given-names></name><name><surname>Klimmeck</surname><given-names>D</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><name><surname>Lipka</surname><given-names>DB</given-names></name><name><surname>Reyes</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Weichenhan</surname><given-names>D</given-names></name><name><surname>Lier</surname><given-names>A</given-names></name><name><surname>von Paleske</surname><given-names>L</given-names></name><name><surname>Renders</surname><given-names>S</given-names></name><name><surname>Wünsche</surname><given-names>P</given-names></name><name><surname>Zeisberger</surname><given-names>P</given-names></name><name><surname>Brocks</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Herrmann</surname><given-names>C</given-names></name><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Essers</surname><given-names>MAG</given-names></name><name><surname>Brors</surname><given-names>B</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Milsom</surname><given-names>MD</given-names></name><name><surname>Plass</surname><given-names>C</given-names></name><name><surname>Krijgsveld</surname><given-names>J</given-names></name><name><surname>Trumpp</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis</article-title><source>Cell Stem Cell</source><volume>15</volume><fpage>507</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.07.005</pub-id><pub-id pub-id-type="pmid">25158935</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>SM</given-names></name><name><surname>Boles</surname><given-names>NC</given-names></name><name><surname>Lin</surname><given-names>K-YK</given-names></name><name><surname>Tierney</surname><given-names>MP</given-names></name><name><surname>Bowman</surname><given-names>TV</given-names></name><name><surname>Bradfute</surname><given-names>SB</given-names></name><name><surname>Chen</surname><given-names>AJ</given-names></name><name><surname>Merchant</surname><given-names>AA</given-names></name><name><surname>Sirin</surname><given-names>O</given-names></name><name><surname>Weksberg</surname><given-names>DC</given-names></name><name><surname>Merchant</surname><given-names>MG</given-names></name><name><surname>Fisk</surname><given-names>CJ</given-names></name><name><surname>Shaw</surname><given-names>CA</given-names></name><name><surname>Goodell</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hematopoietic fingerprints: an expression database of stem cells and their progeny</article-title><source>Cell Stem Cell</source><volume>1</volume><fpage>578</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.10.003</pub-id><pub-id pub-id-type="pmid">18371395</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>Y-H</given-names></name><name><surname>Kim</surname><given-names>Y-J</given-names></name><name><surname>Kim</surname><given-names>Y-W</given-names></name><name><surname>Moon</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>YY</given-names></name><name><surname>Jung</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>H-E</given-names></name><name><surname>Kim</surname><given-names>T-J</given-names></name><name><surname>Cheong</surname><given-names>T-C</given-names></name><name><surname>Moon</surname><given-names>H-J</given-names></name><name><surname>Cho</surname><given-names>J-A</given-names></name><name><surname>Kim</surname><given-names>H-R</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Na</surname><given-names>Y</given-names></name><name><surname>Seok</surname><given-names>S-H</given-names></name><name><surname>Cho</surname><given-names>N-H</given-names></name><name><surname>Lee</surname><given-names>H-C</given-names></name><name><surname>Nam</surname><given-names>E-H</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Minato</surname><given-names>N</given-names></name><name><surname>Seong</surname><given-names>S-Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>1984</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01984</pub-id><pub-id pub-id-type="pmid">30279688</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapple</surname><given-names>RH</given-names></name><name><surname>Tseng</surname><given-names>Y-J</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Kitano</surname><given-names>A</given-names></name><name><surname>Takeichi</surname><given-names>M</given-names></name><name><surname>Hoegenauer</surname><given-names>KA</given-names></name><name><surname>Nakada</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lineage tracing of murine adult hematopoietic stem cells reveals active contribution to steady-state hematopoiesis</article-title><source>Blood Advances</source><volume>2</volume><fpage>1220</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2018016295</pub-id><pub-id pub-id-type="pmid">29848758</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CI</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Datta</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hematopoietic stem and multipotent progenitor cells produce IL-17, IL-21 and other cytokines in response to TLR signals associated with late apoptotic products and augment memory Th17 and Tc17 cells in the bone marrow of normal and lupus mice</article-title><source>Clinical Immunology (Orlando, Fla.)</source><volume>162</volume><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2015.10.007</pub-id><pub-id pub-id-type="pmid">26521071</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>DB</given-names></name><name><surname>Sworder</surname><given-names>B</given-names></name><name><surname>Bouladoux</surname><given-names>N</given-names></name><name><surname>Roy</surname><given-names>CN</given-names></name><name><surname>Uchida</surname><given-names>AM</given-names></name><name><surname>Grigg</surname><given-names>M</given-names></name><name><surname>Robey</surname><given-names>PG</given-names></name><name><surname>Belkaid</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during <italic>Toxoplasma gondii</italic> infection</article-title><source>Journal of Leukocyte Biology</source><volume>92</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1189/jlb.1011527</pub-id><pub-id pub-id-type="pmid">22493080</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delano</surname><given-names>MJ</given-names></name><name><surname>Scumpia</surname><given-names>PO</given-names></name><name><surname>Weinstein</surname><given-names>JS</given-names></name><name><surname>Coco</surname><given-names>D</given-names></name><name><surname>Nagaraj</surname><given-names>S</given-names></name><name><surname>Kelly-Scumpia</surname><given-names>KM</given-names></name><name><surname>O’Malley</surname><given-names>KA</given-names></name><name><surname>Wynn</surname><given-names>JL</given-names></name><name><surname>Antonenko</surname><given-names>S</given-names></name><name><surname>Al-Quran</surname><given-names>SZ</given-names></name><name><surname>Swan</surname><given-names>R</given-names></name><name><surname>Chung</surname><given-names>C-S</given-names></name><name><surname>Atkinson</surname><given-names>MA</given-names></name><name><surname>Ramphal</surname><given-names>R</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name><name><surname>Reeves</surname><given-names>WH</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>J</given-names></name><name><surname>Laface</surname><given-names>D</given-names></name><name><surname>Heyworth</surname><given-names>PG</given-names></name><name><surname>Clare-Salzler</surname><given-names>M</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis</article-title><source>The Journal of Experimental Medicine</source><volume>204</volume><fpage>1463</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1084/jem.20062602</pub-id><pub-id pub-id-type="pmid">17548519</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deutschman</surname><given-names>CS</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Sepsis: current dogma and new perspectives</article-title><source>Immunity</source><volume>40</volume><fpage>463</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.04.001</pub-id><pub-id pub-id-type="pmid">24745331</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efstratiou</surname><given-names>A</given-names></name><name><surname>Lamagni</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>In: <italic>Streptococcus pyogenes</italic>: Basic Biology to Clinical Manifestations</article-title><source>Pathogens (Basel, Switzerland)</source><volume>3</volume><elocation-id>10060776</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10060776</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emgård</surname><given-names>J</given-names></name><name><surname>Bergsten</surname><given-names>H</given-names></name><name><surname>McCormick</surname><given-names>JK</given-names></name><name><surname>Barrantes</surname><given-names>I</given-names></name><name><surname>Skrede</surname><given-names>S</given-names></name><name><surname>Sandberg</surname><given-names>JK</given-names></name><name><surname>Norrby-Teglund</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MAIT Cells Are Major Contributors to the Cytokine Response in Group A Streptococcal Toxic Shock Syndrome</article-title><source>PNAS</source><volume>116</volume><fpage>25923</fpage><lpage>25931</lpage><pub-id pub-id-type="doi">10.1073/pnas.1910883116</pub-id><pub-id pub-id-type="pmid">31772015</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esplin</surname><given-names>BL</given-names></name><name><surname>Shimazu</surname><given-names>T</given-names></name><name><surname>Welner</surname><given-names>RS</given-names></name><name><surname>Garrett</surname><given-names>KP</given-names></name><name><surname>Nie</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Humphrey</surname><given-names>MB</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Borghesi</surname><given-names>LA</given-names></name><name><surname>Kincade</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Chronic exposure to a TLR ligand injures hematopoietic stem cells</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>186</volume><fpage>5367</fpage><lpage>5375</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1003438</pub-id><pub-id pub-id-type="pmid">21441445</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estcourt</surname><given-names>LJ</given-names></name><name><surname>Stanworth</surname><given-names>SJ</given-names></name><name><surname>Hopewell</surname><given-names>S</given-names></name><name><surname>Doree</surname><given-names>C</given-names></name><name><surname>Trivella</surname><given-names>M</given-names></name><name><surname>Massey</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction</article-title><source>The Cochrane Database of Systematic Reviews</source><volume>4</volume><elocation-id>CD005339</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD005339.pub2</pub-id><pub-id pub-id-type="pmid">27128488</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fajgenbaum</surname><given-names>DC</given-names></name><name><surname>June</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cytokine Storm</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>2255</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1056/NEJMra2026131</pub-id><pub-id pub-id-type="pmid">33264547</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>K</given-names></name><name><surname>Paust</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>10</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.00425</pub-id><pub-id pub-id-type="pmid">32974217</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gekas</surname><given-names>C</given-names></name><name><surname>Graf</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CD41 expression marks myeloid-biased adult hematopoietic stem cells and increases with age</article-title><source>Blood</source><volume>121</volume><fpage>4463</fpage><lpage>4472</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-09-457929</pub-id><pub-id pub-id-type="pmid">23564910</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DAMP-sensing receptors in sterile inflammation and inflammatory diseases</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>95</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0215-7</pub-id><pub-id pub-id-type="pmid">31558839</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidalgo</surname><given-names>A</given-names></name><name><surname>Chilvers</surname><given-names>ER</given-names></name><name><surname>Summers</surname><given-names>C</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Neutrophil Life Cycle</article-title><source>Trends in Immunology</source><volume>40</volume><fpage>584</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/j.it.2019.04.013</pub-id><pub-id pub-id-type="pmid">31153737</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>K-J</given-names></name><name><surname>Su</surname><given-names>I-J</given-names></name><name><surname>Theron</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Y-C</given-names></name><name><surname>Lai</surname><given-names>S-K</given-names></name><name><surname>Liu</surname><given-names>C-C</given-names></name><name><surname>Lei</surname><given-names>H-Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>An interferon-gamma-related cytokine storm in SARS patients</article-title><source>Journal of Medical Virology</source><volume>75</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1002/jmv.20255</pub-id><pub-id pub-id-type="pmid">15602737</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffer</surname><given-names>U</given-names></name><name><surname>Wade</surname><given-names>RG</given-names></name><name><surname>Gourlay</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cytokines in the systemic inflammatory response syndrome: a review</article-title><source>HSR Proceedings</source><volume>2</volume><fpage>161</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">23441054</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>BR</given-names></name><name><surname>Tuladhar</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Zalduondo</surname><given-names>L</given-names></name><name><surname>Samir</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Sundaram</surname><given-names>B</given-names></name><name><surname>Banoth</surname><given-names>B</given-names></name><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Schreiner</surname><given-names>P</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Webby</surname><given-names>R</given-names></name><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Kanneganti</surname><given-names>T-D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes</article-title><source>Cell</source><volume>184</volume><fpage>149</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id><pub-id pub-id-type="pmid">33278357</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpova</surname><given-names>D</given-names></name><name><surname>Ritchey</surname><given-names>JK</given-names></name><name><surname>Holt</surname><given-names>MS</given-names></name><name><surname>Abou-Ezzi</surname><given-names>G</given-names></name><name><surname>Monlish</surname><given-names>D</given-names></name><name><surname>Batoon</surname><given-names>L</given-names></name><name><surname>Millard</surname><given-names>S</given-names></name><name><surname>Spohn</surname><given-names>G</given-names></name><name><surname>Wiercinska</surname><given-names>E</given-names></name><name><surname>Chendamarai</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Christ</surname><given-names>S</given-names></name><name><surname>Gehrs</surname><given-names>L</given-names></name><name><surname>Schuettpelz</surname><given-names>LG</given-names></name><name><surname>Dembowsky</surname><given-names>K</given-names></name><name><surname>Pettit</surname><given-names>AR</given-names></name><name><surname>Rettig</surname><given-names>MP</given-names></name><name><surname>Bonig</surname><given-names>H</given-names></name><name><surname>DiPersio</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells</article-title><source>Blood</source><volume>129</volume><fpage>2939</fpage><lpage>2949</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-10-746909</pub-id><pub-id pub-id-type="pmid">28400375</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Castillo</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Historical Perspectives, Current Status, and Ethical Issues in Granulocyte Transfusion</article-title><source>Annals of Clinical and Laboratory Science</source><volume>47</volume><fpage>501</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">28801379</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Köstlin</surname><given-names>N</given-names></name><name><surname>Vogelmann</surname><given-names>M</given-names></name><name><surname>Spring</surname><given-names>B</given-names></name><name><surname>Schwarz</surname><given-names>J</given-names></name><name><surname>Feucht</surname><given-names>J</given-names></name><name><surname>Härtel</surname><given-names>C</given-names></name><name><surname>Orlikowsky</surname><given-names>TW</given-names></name><name><surname>Poets</surname><given-names>CF</given-names></name><name><surname>Gille</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Granulocytic myeloid-derived suppressor cells from human cord blood modulate T-helper cell response towards an anti-inflammatory phenotype</article-title><source>Immunology</source><volume>152</volume><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/imm.12751</pub-id><pub-id pub-id-type="pmid">28464218</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>J</given-names></name><name><surname>Hillenbrand</surname><given-names>A</given-names></name><name><surname>Tsagogiorgas</surname><given-names>C</given-names></name><name><surname>Patry</surname><given-names>C</given-names></name><name><surname>Tönshoff</surname><given-names>B</given-names></name><name><surname>Yard</surname><given-names>B</given-names></name><name><surname>Beck</surname><given-names>G</given-names></name><name><surname>Rafat</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Intravenous delivery of granulocyte-macrophage colony stimulating factor impairs survival in lipopolysaccharide-induced sepsis</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e218602</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0218602</pub-id><pub-id pub-id-type="pmid">31220157</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larcombe</surname><given-names>AN</given-names></name><name><surname>Foong</surname><given-names>RE</given-names></name><name><surname>Bozanich</surname><given-names>EM</given-names></name><name><surname>Berry</surname><given-names>LJ</given-names></name><name><surname>Garratt</surname><given-names>LW</given-names></name><name><surname>Gualano</surname><given-names>RC</given-names></name><name><surname>Jones</surname><given-names>JE</given-names></name><name><surname>Dousha</surname><given-names>LF</given-names></name><name><surname>Zosky</surname><given-names>GR</given-names></name><name><surname>Sly</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Sexual dimorphism in lung function responses to acute influenza A infection</article-title><source>Influenza and Other Respiratory Viruses</source><volume>5</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1111/j.1750-2659.2011.00236.x</pub-id><pub-id pub-id-type="pmid">21668688</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Effects of immunotherapy on mortality in neonates with suspected or proven sepsis: a systematic review and network meta-analysis</article-title><source>BMC Pediatrics</source><volume>19</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12887-019-1609-1</pub-id><pub-id pub-id-type="pmid">31383021</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacNamara</surname><given-names>KC</given-names></name><name><surname>Oduro</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>O</given-names></name><name><surname>Jones</surname><given-names>DD</given-names></name><name><surname>McLaughlin</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Borjesson</surname><given-names>DL</given-names></name><name><surname>Winslow</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Infection-induced myelopoiesis during intracellular bacterial infection is critically dependent upon IFN-γ signaling</article-title><source>Journal of Immunology (Baltimore, Md</source><volume>186</volume><fpage>1032</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001893</pub-id><pub-id pub-id-type="pmid">21149601</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maizels</surname><given-names>RM</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulatory T cells in infection</article-title><source>Advances in Immunology</source><volume>112</volume><fpage>73</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-387827-4.00003-6</pub-id><pub-id pub-id-type="pmid">22118407</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matatall</surname><given-names>KA</given-names></name><name><surname>Shen</surname><given-names>CC</given-names></name><name><surname>Challen</surname><given-names>GA</given-names></name><name><surname>King</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Type II interferon promotes differentiation of myeloid-biased hematopoietic stem cells</article-title><source>Stem Cells (Dayton, Ohio)</source><volume>32</volume><fpage>3023</fpage><lpage>3030</lpage><pub-id pub-id-type="doi">10.1002/stem.1799</pub-id><pub-id pub-id-type="pmid">25078851</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matatall</surname><given-names>KA</given-names></name><name><surname>Jeong</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Mo</surname><given-names>Q</given-names></name><name><surname>Kimmel</surname><given-names>M</given-names></name><name><surname>King</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation</article-title><source>Cell Reports</source><volume>17</volume><fpage>2584</fpage><lpage>2595</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.031</pub-id><pub-id pub-id-type="pmid">27926863</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathias</surname><given-names>B</given-names></name><name><surname>Szpila</surname><given-names>BE</given-names></name><name><surname>Moore</surname><given-names>FA</given-names></name><name><surname>Efron</surname><given-names>PA</given-names></name><name><surname>Moldawer</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A Review of GM-CSF Therapy in Sepsis</article-title><source>Medicine</source><volume>94</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1097/MD.0000000000002044</pub-id><pub-id pub-id-type="pmid">26683913</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metsalu</surname><given-names>T</given-names></name><name><surname>Vilo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>W566</fpage><lpage>W570</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv468</pub-id><pub-id pub-id-type="pmid">25969447</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales-Mantilla</surname><given-names>DE</given-names></name><name><surname>King</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease</article-title><source>Current Stem Cell Reports</source><volume>4</volume><fpage>264</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s40778-018-0139-3</pub-id><pub-id pub-id-type="pmid">30148048</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>Y</given-names></name><name><surname>Garrett</surname><given-names>KP</given-names></name><name><surname>Ohta</surname><given-names>S</given-names></name><name><surname>Bahrun</surname><given-names>U</given-names></name><name><surname>Kouro</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Takatsu</surname><given-names>K</given-names></name><name><surname>Kincade</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment</article-title><source>Immunity</source><volume>24</volume><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.04.008</pub-id><pub-id pub-id-type="pmid">16782035</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napolitano</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Sepsis 2018: Definitions and Guideline Changes</article-title><source>Surgical Infections</source><volume>19</volume><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1089/sur.2017.278</pub-id><pub-id pub-id-type="pmid">29447109</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paget</surname><given-names>C</given-names></name><name><surname>Trottein</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanisms of Bacterial Superinfection Post-influenza: A Role for Unconventional T Cells</article-title><source>Frontiers in Immunology</source><volume>10</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00336</pub-id><pub-id pub-id-type="pmid">30881357</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>Mirantes-Barbeito</surname><given-names>C</given-names></name><name><surname>Fong</surname><given-names>S</given-names></name><name><surname>Loeffler</surname><given-names>D</given-names></name><name><surname>Kovtonyuk</surname><given-names>LV</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Lakshminarasimhan</surname><given-names>R</given-names></name><name><surname>Chin</surname><given-names>CP</given-names></name><name><surname>Techner</surname><given-names>J-M</given-names></name><name><surname>Will</surname><given-names>B</given-names></name><name><surname>Nerlov</surname><given-names>C</given-names></name><name><surname>Steidl</surname><given-names>U</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name><name><surname>Passegué</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal</article-title><source>Nature Cell Biology</source><volume>18</volume><fpage>607</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1038/ncb3346</pub-id><pub-id pub-id-type="pmid">27111842</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>TH</given-names></name><name><surname>Boeckh</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>RW</given-names></name><name><surname>McCullough</surname><given-names>J</given-names></name><name><surname>Ness</surname><given-names>PM</given-names></name><name><surname>Strauss</surname><given-names>RG</given-names></name><name><surname>Nichols</surname><given-names>WG</given-names></name><name><surname>Hamza</surname><given-names>TH</given-names></name><name><surname>Cushing</surname><given-names>MM</given-names></name><name><surname>King</surname><given-names>KE</given-names></name><name><surname>Young</surname><given-names>J-AH</given-names></name><name><surname>Williams</surname><given-names>E</given-names></name><name><surname>McFarland</surname><given-names>J</given-names></name><name><surname>Holter Chakrabarty</surname><given-names>J</given-names></name><name><surname>Sloan</surname><given-names>SR</given-names></name><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Parekh</surname><given-names>S</given-names></name><name><surname>Sachais</surname><given-names>BS</given-names></name><name><surname>Kiss</surname><given-names>JE</given-names></name><name><surname>Assmann</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection</article-title><source>Blood</source><volume>126</volume><fpage>2153</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-05-645986</pub-id><pub-id pub-id-type="pmid">26333778</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>TM</given-names></name><name><surname>Hamad</surname><given-names>Y</given-names></name><name><surname>Pande</surname><given-names>A</given-names></name><name><surname>Varon</surname><given-names>J</given-names></name><name><surname>O’Brien</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name><name><surname>Warren</surname><given-names>DK</given-names></name><name><surname>Dantes</surname><given-names>RB</given-names></name><name><surname>Epstein</surname><given-names>L</given-names></name><name><surname>Klompas</surname><given-names>M</given-names></name><collab>Centers for Disease Control and Prevention Prevention Epicenters Program</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals</article-title><source>JAMA Network Open</source><volume>2</volume><elocation-id>e187571</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.7571</pub-id><pub-id pub-id-type="pmid">30768188</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>SP</given-names></name><name><surname>Marks</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Granulocyte transfusions in the G-CSF er: Where do we stand?</article-title><source>Bone Marrow Transplantation</source><volume>34</volume><fpage>839</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1038/sj.bmt.1704630</pub-id><pub-id pub-id-type="pmid">15273712</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Fraticelli</surname><given-names>AE</given-names></name><name><surname>Wolock</surname><given-names>SL</given-names></name><name><surname>Weinreb</surname><given-names>CS</given-names></name><name><surname>Panero</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>SH</given-names></name><name><surname>Jankovic</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Calogero</surname><given-names>RA</given-names></name><name><surname>Klein</surname><given-names>AM</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Clonal analysis of lineage fate in native haematopoiesis</article-title><source>Nature</source><volume>553</volume><fpage>212</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/nature25168</pub-id><pub-id pub-id-type="pmid">29323290</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosser</surname><given-names>EC</given-names></name><name><surname>Mauri</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulatory B cells: origin, phenotype, and function</article-title><source>Immunity</source><volume>42</volume><fpage>607</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.04.005</pub-id><pub-id pub-id-type="pmid">25902480</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rynda-Apple</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>KM</given-names></name><name><surname>Alcorn</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease</article-title><source>Infection and Immunity</source><volume>83</volume><fpage>3764</fpage><lpage>3770</lpage><pub-id pub-id-type="doi">10.1128/IAI.00298-15</pub-id><pub-id pub-id-type="pmid">26216421</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Kamio</surname><given-names>N</given-names></name><name><surname>Yokota</surname><given-names>A</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>A</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Maekawa</surname><given-names>T</given-names></name><name><surname>Hirai</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>C/EBPβ isoforms sequentially regulate regenerating mouse hematopoietic stem/progenitor cells</article-title><source>Blood Advances</source><volume>4</volume><fpage>3343</fpage><lpage>3356</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2018022913</pub-id><pub-id pub-id-type="pmid">32717031</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrijver</surname><given-names>IT</given-names></name><name><surname>Théroude</surname><given-names>C</given-names></name><name><surname>Roger</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Myeloid-Derived Suppressor Cells in Sepsis</article-title><source>Frontiers in Immunology</source><volume>10</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00327</pub-id><pub-id pub-id-type="pmid">30873175</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Mass</surname><given-names>E</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation</article-title><source>Immunity</source><volume>50</volume><fpage>288</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.01.019</pub-id><pub-id pub-id-type="pmid">30784577</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schürch</surname><given-names>CM</given-names></name><name><surname>Riether</surname><given-names>C</given-names></name><name><surname>Ochsenbein</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cytotoxic CD8+ T cells stimulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells</article-title><source>Cell Stem Cell</source><volume>14</volume><fpage>460</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.01.002</pub-id><pub-id pub-id-type="pmid">24561082</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skirecki</surname><given-names>T</given-names></name><name><surname>Mikaszewska-Sokolewicz</surname><given-names>M</given-names></name><name><surname>Godlewska</surname><given-names>M</given-names></name><name><surname>Dołęgowska</surname><given-names>B</given-names></name><name><surname>Czubak</surname><given-names>J</given-names></name><name><surname>Hoser</surname><given-names>G</given-names></name><name><surname>Kawiak</surname><given-names>J</given-names></name><name><surname>Zielińska-Borkowska</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mobilization of Stem and Progenitor Cells in Septic Shock Patients</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>3289</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-39772-4</pub-id><pub-id pub-id-type="pmid">30824730</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Influenza A virus infection kinetics: quantitative data and models</article-title><source>Wiley Interdisciplinary Reviews. Systems Biology and Medicine</source><volume>3</volume><fpage>429</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1002/wsbm.129</pub-id><pub-id pub-id-type="pmid">21197654</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ramos</surname><given-names>A</given-names></name><name><surname>Chapman</surname><given-names>B</given-names></name><name><surname>Johnnidis</surname><given-names>JB</given-names></name><name><surname>Le</surname><given-names>L</given-names></name><name><surname>Ho</surname><given-names>Y-J</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Hofmann</surname><given-names>O</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal dynamics of native haematopoiesis</article-title><source>Nature</source><volume>514</volume><fpage>322</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/nature13824</pub-id><pub-id pub-id-type="pmid">25296256</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takizawa</surname><given-names>H</given-names></name><name><surname>Fritsch</surname><given-names>K</given-names></name><name><surname>Kovtonyuk</surname><given-names>LV</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Yakkala</surname><given-names>C</given-names></name><name><surname>Jacobs</surname><given-names>K</given-names></name><name><surname>Ahuja</surname><given-names>AK</given-names></name><name><surname>Lopes</surname><given-names>M</given-names></name><name><surname>Hausmann</surname><given-names>A</given-names></name><name><surname>Hardt</surname><given-names>W-D</given-names></name><name><surname>Gomariz</surname><given-names>Á</given-names></name><name><surname>Nombela-Arrieta</surname><given-names>C</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness</article-title><source>Cell Stem Cell</source><volume>21</volume><fpage>225</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2017.06.013</pub-id><pub-id pub-id-type="pmid">28736216</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teofili</surname><given-names>L</given-names></name><name><surname>Valentini</surname><given-names>CG</given-names></name><name><surname>Di Blasi</surname><given-names>R</given-names></name><name><surname>Orlando</surname><given-names>N</given-names></name><name><surname>Fianchi</surname><given-names>L</given-names></name><name><surname>Zini</surname><given-names>G</given-names></name><name><surname>Sica</surname><given-names>S</given-names></name><name><surname>De Stefano</surname><given-names>V</given-names></name><name><surname>Pagano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e159569</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0159569</pub-id><pub-id pub-id-type="pmid">27487075</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tijaro-Ovalle</surname><given-names>NM</given-names></name><name><surname>Karantanos</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>HT</given-names></name><name><surname>Boussiotis</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease</article-title><source>Frontiers in Immunology</source><volume>10</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00295</pub-id><pub-id pub-id-type="pmid">30891031</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname><given-names>CL</given-names></name><name><surname>Peters</surname><given-names>W</given-names></name><name><surname>Si</surname><given-names>Y</given-names></name><name><surname>Slaymaker</surname><given-names>S</given-names></name><name><surname>Aslanian</surname><given-names>AM</given-names></name><name><surname>Weisberg</surname><given-names>SP</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Charo</surname><given-names>IF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites</article-title><source>The Journal of Clinical Investigation</source><volume>117</volume><fpage>902</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1172/JCI29919</pub-id><pub-id pub-id-type="pmid">17364026</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhel</surname><given-names>F</given-names></name><name><surname>Azzaoui</surname><given-names>I</given-names></name><name><surname>Grégoire</surname><given-names>M</given-names></name><name><surname>Pangault</surname><given-names>C</given-names></name><name><surname>Dulong</surname><given-names>J</given-names></name><name><surname>Tadié</surname><given-names>J-M</given-names></name><name><surname>Gacouin</surname><given-names>A</given-names></name><name><surname>Camus</surname><given-names>C</given-names></name><name><surname>Cynober</surname><given-names>L</given-names></name><name><surname>Fest</surname><given-names>T</given-names></name><name><surname>Le Tulzo</surname><given-names>Y</given-names></name><name><surname>Roussel</surname><given-names>M</given-names></name><name><surname>Tarte</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>196</volume><fpage>315</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1164/rccm.201606-1143OC</pub-id><pub-id pub-id-type="pmid">28146645</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Poll</surname><given-names>T</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Scicluna</surname><given-names>BP</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The immunopathology of sepsis and potential therapeutic targets</article-title><source>Nature Reviews. Immunology</source><volume>17</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.36</pub-id><pub-id pub-id-type="pmid">28436424</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>MJ</given-names></name><name><surname>Barnett</surname><given-names>TC</given-names></name><name><surname>McArthur</surname><given-names>JD</given-names></name><name><surname>Cole</surname><given-names>JN</given-names></name><name><surname>Gillen</surname><given-names>CM</given-names></name><name><surname>Henningham</surname><given-names>A</given-names></name><name><surname>Sriprakash</surname><given-names>KS</given-names></name><name><surname>Sanderson-Smith</surname><given-names>ML</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Disease manifestations and pathogenic mechanisms of Group A Streptococcus</article-title><source>Clinical Microbiology Reviews</source><volume>27</volume><fpage>264</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1128/CMR.00101-13</pub-id><pub-id pub-id-type="pmid">24696436</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S-M</given-names></name><name><surname>Lu</surname><given-names>I-H</given-names></name><name><surname>Lin</surname><given-names>Y-L</given-names></name><name><surname>Lin</surname><given-names>Y-S</given-names></name><name><surname>Wu</surname><given-names>J-J</given-names></name><name><surname>Chuang</surname><given-names>W-J</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Liu</surname><given-names>C-C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The severity of <italic>Streptococcus pyogenes</italic> infections in children is significantly associated with plasma levels of inflammatory cytokines</article-title><source>Diagnostic Microbiology and Infectious Disease</source><volume>61</volume><fpage>165</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2008.01.008</pub-id><pub-id pub-id-type="pmid">18296003</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Long</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The mechanisms of pathological extramedullary hematopoiesis in diseases</article-title><source>Cellular and Molecular Life Sciences</source><volume>77</volume><fpage>2723</fpage><lpage>2738</lpage><pub-id pub-id-type="doi">10.1007/s00018-020-03450-w</pub-id><pub-id pub-id-type="pmid">31974657</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Teng</surname><given-names>Z</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e28680</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0028680</pub-id><pub-id pub-id-type="pmid">22174866</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74561.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Radboudumc Center for Infectious Diseases</institution><country>Netherlands</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.10.26.465915" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.26.465915"/></front-stub><body><p>This preclinical study reports on a novel strategy for sepsis. Sepsis induced by Group A Streptococcus (GAS) in mice leads to depletion of bone marrow HSPCs and mortality and infusion of naive donor HSPCs lower mortality but has no effect on bacterial burden. This supports that HSPCs infusion might attenuate the detrimental immune response in sepsis warranting further investigation of this novel concept.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74561.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name><role>Reviewing Editor</role><aff><institution>Radboudumc Center for Infectious Diseases</institution><country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.26.465915">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.10.26.465915v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Hematopoietic stem and progenitor cells improve survival from sepsis by boosting immunomodulatory cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jos Van der Meer as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>General comments:</p><p>The reviewers comment that the authors are a bit too optimistic in stating &quot;Our findings could lead to the development of an efficacious new therapeutic approach that could succeed where granulocyte infusions have fallen short&quot;. There are so many steps and hurdles that need to be taken before this kind of intervention could be translated to the clinic.</p><p>In addition, the data presented in figure 7 is of little value, as these were obtained in non-inflamed/infected mice. Therefore, conclusions such as &quot;Whereas MDSCs did arise directly from infused cells, their numbers were not sufficient to account for the large increase in MDSCs observed in the HSPC-rescued mice. These data suggest that HSPC infusion contributes to MDSC expansion via both direct and indirect mechanisms.&quot; are not justified.</p><p>Please adjust this conclusion and soften the statements regarding the translation to the clinical setting throughout the manuscript.</p><p>More specific comments that need to be addressed:</p><p>1) Can the authors explain why MPP4 is also depleted following GAS (Figure 2F), as this is a lymphoid progenitor rather than a myeloid one. This appears not to be congruent with the lack of depletion of BM T- and B-cells (Figure 1E-F).</p><p>2) In Figure 2, why were different gating/markers for MPP2/3/4 used in the BM compared with the spleen?</p><p>3) The authors state: &quot;This finding suggests that the loss of BM HSPC populations is not simply a result of migration from the BM into the spleen&quot; However, there is a significant increase in HSPCs in the spleen (Figure 2G), so why discard this possibility? How can these number/proportions be directly compared?</p><p>4) Spleen subpopulations in Figure 2 are expressed as % of total spleen cells, but there is no data showing whether or not there was there a change in total spleen cells?</p><p>5) What is shown in figure 4B? Which organ?</p><p>6) At what timepoint were samples taken for the analyses presented in Figure 6A-E?</p><p>7) The authors need to explain why they used the specific model of sepsis with <italic>Streptococcus pyogenes</italic> instead of the classical models of LPS injection or whole bacteria injection or cecal ligation and puncture. They also need to provide evidence that the studied model was accompanied by organ failure through the measurement of dry to wet lung ratio, serum creatinine and serum aminotransferases.</p><p>8) A detailed methodology on the isolation of progenitor cells is needed. The authors need also to explain if they used an autograph or allograph approach.</p><p>9) How did the authors adjust for any graft versus host reaction?</p><p>10) Where other bacterial species isolated from the liver? Why were not kidney and lung cultures being performed?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74561.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>General comments:</p><p>The reviewers comment that the authors are a bit too optimistic in stating &quot;Our findings could lead to the development of an efficacious new therapeutic approach that could succeed where granulocyte infusions have fallen short&quot;. There are so many steps and hurdles that need to be taken before this kind of intervention could be translated to the clinic.</p></disp-quote><p>We appreciate the help in making this part of the conclusions clearer. We are aware of the multitude of steps needed before a clinical application and we have rephrased our conclusion as:</p><p>“While the path to a clinical application can be long, our findings could lead to the future development of a new therapeutic approach that could succeed where granulocyte infusions have fallen short.”</p><disp-quote content-type="editor-comment"><p>In addition, the data presented in figure 7 is of little value, as these were obtained in non-inflamed/infected mice. Therefore, conclusions such as &quot;Whereas MDSCs did arise directly from infused cells, their numbers were not sufficient to account for the large increase in MDSCs observed in the HSPC-rescued mice. These data suggest that HSPC infusion contributes to MDSC expansion via both direct and indirect mechanisms.&quot; are not justified.</p><p>Please adjust this conclusion and soften the statements regarding the translation to the clinical setting throughout the manuscript.</p></disp-quote><p>We thank the reviewer for this comment. With regards to figure 7, these mice were in fact infected and showed clear signs of inflammation (swelling, redness, abscess). They were infected at day 0, infused with HSPCs at day 1, and analyzed at day 30 for BM and peripheral blood phenotypes. Even at day 30, the mice had a residual abscess and thus the data reflect an inflamed/infected environment.</p><p>In order to clarify this point, we have included a more detailed timeline and treatment description of the mice in the Results section of the manuscript as follows:</p><p>“In order to determine whether HSPCs infused in an infected mouse directly differentiate into MDSCs, we performed lineage tracing experiments using expression of the CD45.1 variant to distinguish infused HSPCs from endogenous CD45.2 cells. Mice were infected with GAS and then rescued with HSPCs 24h after GAS inoculation. Thirty days after infection, mice still showed signs of inflammation on the leg, indicating the inflammatory cues that drive HSPC activation and differentiation were still present. At thirty days after infection, the CD45.1+ cell compartment showed no HSCs but a low number of MPP1 and myeloid biased MPP3s in the BM (Figure 7A).”</p><disp-quote content-type="editor-comment"><p>More specific comments that need to be addressed:</p><p>1) Can the authors explain why MPP4 is also depleted following GAS (Figure 2F), as this is a lymphoid progenitor rather than a myeloid one. This appears not to be congruent with the lack of depletion of BM T- and B-cells (Figure 1E-F).</p></disp-quote><p>We thank the reviewer for this observation. While MPP4s are certainly lymphoid biased, they are known to have plasticity in their differentiation pathways. Furthermore, the lymphoid compartment (T and B cells) tends to be much longer-lived than myeloid cells such as neutrophils and monocytes. In addition, myeloid cells are massively mobilized during an acute infection whereas the shifts in lymphoid cells are more limited. For all of these reasons, an acute depletion of lymphoid progenitors does not necessarily result in an immediate loss of T and B cells.</p><disp-quote content-type="editor-comment"><p>2) In Figure 2, why were different gating/markers for MPP2/3/4 used in the BM compared with the spleen?</p></disp-quote><p>These MPPs are extremely rare in the spleen. Using BM markers would obviate the detection of any cells in the spleen. Thus, we decided to include a broader population in the spleen to detect these populations. Other groups studying spleen hematopoietic cells have also used these markers to describe spleen HSPCs and HSCs (Oda et al., <italic>Scientific Reports</italic>, 2018; Burberry et al., <italic>Cell Host and Microbe</italic>, 2014).</p><disp-quote content-type="editor-comment"><p>3) The authors state: &quot;This finding suggests that the loss of BM HSPC populations is not simply a result of migration from the BM into the spleen&quot; However, there is a significant increase in HSPCs in the spleen (Figure 2G), so why discard this possibility? How can these number/proportions be directly compared?</p></disp-quote><p>We agree with the reviewer that this possibility should not be discarded. However, that magnitude of BM depletion and the small or no changes in the corresponding spleen populations suggests that this is not solely by migration. We appreciate the reviewers pointing this out and have amended the manuscript to read:</p><p>“These findings suggest that the loss of BM HSPC populations is not principally a result of migration from the BM into the spleen, and other mechanisms such as terminal differentiation also likely contribute to the noted HSPC depletion, as observed in other studies.”</p><disp-quote content-type="editor-comment"><p>4) Spleen subpopulations in Figure 2 are expressed as % of total spleen cells, but there is no data showing whether or not there was there a change in total spleen cells?</p></disp-quote><p>Absolute numbers in the spleen are not available. However, we did measure total spleen size to determine whether there was a change in cellularity of the spleen.</p><p><xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> shows spleen sizes of naïve and GAS-infected mice 72hrs post-infection. We did not detect any difference in spleen size or weight 24-72 hours after GAS infection, therefore it is reasonable to conclude that a change in % of total spleen cells does reflect a corresponding change in absolute number.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>5) What is shown in figure 4B? Which organ?</p></disp-quote><p>As stated in the figure legend, the figure shows a “Flow plot of HSPC gating and representation of different surface expressions of cKit and Sca-1 during infection. Plots are gated from lineage negative BM cells.” The organ of origin of these cells is the bone marrow (BM).</p><disp-quote content-type="editor-comment"><p>6) At what timepoint were samples taken for the analyses presented in Figure 6A-E?</p></disp-quote><p>This data was collected 3 days post-infection and 2 days after HSPC infusion. We have stated this more clearly in the manuscript as follows:</p><p>“Upon analysis of PB and BM populations 3 days after infection and 2 days after HSPC infusion…”</p><disp-quote content-type="editor-comment"><p>7) The authors need to explain why they used the specific model of sepsis with <italic>Streptococcus pyogenes</italic> instead of the classical models of LPS injection or whole bacteria injection or cecal ligation and puncture. They also need to provide evidence that the studied model was accompanied by organ failure through the measurement of dry to wet lung ratio, serum creatinine and serum aminotransferases.</p></disp-quote><p>We appreciate this observation. We mention in the introduction that GAS is a clinically relevant strain that causes a significant disease burden (Gonzalez-Abad and Sanz, Anales de Pediatría, 2020; Terao and Kawabata, Tanpakushitsu Kakusan Koso, 2009; Beres et al., mBio, 2016; Flores and Shelburne, Clinical Infectious Diseases, 2019). It also induces an IFN-mediated immune response, which, in light of prior studies, led us to hypothesize that HSPCs might have a role to play in the response to GAS (Baldridge et al., Trends in Immunology, 2011; Hormaechea-Agulla et al., Cell Stem Cell, 2021; Matatall et al., Stem Cells, 2014; Matatall et al., Cell Reports, 2016).</p><p>We did carefully examine the impact of GAS infection on various organs. While at 3 days post-infection, we did not see a significant difference in serum creatinine and aminotransferases, we did see a significant drop in the albumin-globulin ratio (AGR). Low AGR has been described to be a biomarker of sepsis (Lu et al., <italic>Translational Andrology and Urology</italic>, 2020). Systemic inflammation (Figure 6F) and pathogen dissemination (Figure 4J) are also signs of sepsis.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74561-sa2-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>8) A detailed methodology on the isolation of progenitor cells is needed. The authors need also to explain if they used an autograph or allograph approach.</p></disp-quote><p>We have expanded on our strategy for HSPC isolation in the methods section subtitled “<italic>HSPC isolation and purification”</italic> in order to provide a thorough description of the methods. The infused HSPCs are from naïve donor mice, thus, this is an allogeneic infusion.</p><disp-quote content-type="editor-comment"><p>9) How did the authors adjust for any graft versus host reaction?</p></disp-quote><p>The congenic bone marrow transplant model used in our studies are a well-established system developed over 30 years ago which relies on a variant of a blood epitope that is not immunogenic and therefore does not cause GVHD (Brochu S. Blood 1994 84(9):3221-8). In the setting of GVHD, the immune response of the “graft” against the host can be evidenced by increased inflammation and organ failure if left unattended. However, in our model, we see an overall decrease in inflammation and increased survival of mice for over a month, which also supports the well-established concept that there is no immune response from the infused cells against host cells.</p><disp-quote content-type="editor-comment"><p>10) Where other bacterial species isolated from the liver? Why were not kidney and lung cultures being performed?</p></disp-quote><p>We cultured limb tissue to determine bacterial load as this is the initial site of infection. We cultured the spleen as this is the most likely site of pathogen dissemination during a systemic infection. Spleen data suggests that there is in fact dissemination of GAS to other organs. Note that bacterial culture on nonselective media did not show other bacterial species in the spleen, therefore we would not suspect other bacterial species in the liver. Furthermore, histology did not show other bacterial species in the liver.</p></body></sub-article></article>